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7Abstract
The aim of the present study was to iden-
tify chromosomal and molecular changes in
endometrial, fallopian tube and ovarian car-
cinomas, with emphasis on the serous his-
tological type. More detailed mapping of
chromosomal regions that showed frequent
losses in comparative genomic hybridiza-
tion was performed using allelic analysis.
The expression of known and potential tu-
mor suppressor genes was examined by
Northern blotting and immunohistochemi-
cal staining of ovarian carcinoma tissue
microarrays. To understand the relationship
between genetic and molecular changes and
the biological and clinical behavior of the
tumors, associations of the changes with
clinicopathological characteristics and out-
come of the patients were evaluated.
Comparative genomic hybridization
analyses revealed distinct chromosomal
changes in serous and endometrioid en-
dometrial carcinomas. The changes were fre-
quent and complex in serous carcinoma,
which showed recurrent copy number gains
at 3q, 8q, 5p, 6p and 1q. In the endo-
metrioid type, the changes were less com-
mon and the most frequent aberration was
gain at chromosome arm 1q. In the serous
type, the number of alterations was associ-
ated with patient survival. These findings
are in line with the aggressive behavior of
serous carcinoma, and suggest distinct ge-
netic backgrounds for these two histologi-
cal types of endometrial carcinoma.
In serous fallopian tube carcinoma, re-
current and complex chromosomal alter-
ations were identified, the most common
regions of increased copy number being at
3q, 8q, 1q, 5p, 7q and 12p, and decreased
copy number at 8p and 18q. The changes
found were compared with those detected
in serous carcinomas of the endometrium
and ovary. The patterns of genomic alter-
ations found in these serous carcinomas were
very similar, suggesting that their molecu-
lar pathogeneses may be alike.
Allelotype analyses of distal 8p and dis-
tal 18q revealed more frequent and exten-
sive allelic losses in serous than in muci-
nous ovarian carcinomas, which is in keep-
ing with distinct molecular backgrounds of
these carcinomas. Both LOH at 8p and 18q
were associated with the grade of serous
carcinomas, and LOH at 18q also with pa-
tient survival. In serous carcinoma, mini-
mal common regions of loss, potential lo-
cations of tumor suppressor genes, were
defined: three at 8p21.1-p23.1 and two at
18q22-q23. Expression of a transcription
factor gene, GATA4, located at 8p23.1, was
found to be lost in most serous carcinomas,
but retained in the majority of mucinous
carcinomas. The expression of each of three
candidate tumor suppressor genes, SMAD4,
SMAD2 and DCC, located at 18q21.1, was
reduced or lost in approximately 30% of
serous carcinomas. An association between
allelic loss at 18q21.1 and expression sta-
tus of SMAD4, SMAD2 and DCC was
found, but there was still a proportion of
tumors showing LOH without loss of ex-
pression of these genes, supporting the ex-
istence of other tumor suppressor genes
more distally at 18q.
Immunohistochemical staining of P53
protein in tissue microarrays showed weak
immunopositivity in a proportion of nor-
mal epithelial cells and a similar pattern of
staining in 41% of serous ovarian carcino-
mas. Two distinct patterns of aberrant P53
staining were identified in the carcinomas:
excessive staining in 43% and completely
negative staining in 16%. Both of these
aberrant patterns of P53 staining were as-
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sociated with aggressive clinicopathologi-
cal characteristics of the tumors and poor
overall survival. In multivariate analysis,
P53 expression status was identified as an
independent prognostic factor for overall
survival. In addition, aberrant P53 expres-
sion was associated with a poor response to
therapy and a shorter disease-free survival
period. Both in stage I and stage III serous
ovarian carcinomas, P53 expression status
showed a potential to serve as a useful prog-
nostic marker.
Gynecological carcinomas are heteroge-
neous diseases, and understanding of their
molecular pathogenesis is needed for devel-
opment of more individual cancer therapies.
The similarity of changes detected in se-
rous carcinomas of various gynecological
organs and distinctiveness versus changes
found in other histological types provides
better understanding of the biological be-
havior and underlines the importance of
histological type in classification of these
carcinomas. In addition to understanding
the biology of the disease, molecular mark-
ers are needed for predicting the outcome
of individual patients and making treatment
decisions. In the future, knowledge of the
genomic sequence and high-throughput
expression analyses will aid in discovery of
the underlying genes located in the regions
defined in the present study.
9Introduction
Uterine and ovarian cancers are the third
and the fourth most common cancers
among women in Finland, whereas fallo-
pian tube cancer is a relatively rare disease.
Most cancers of the ovary, the fallopian tube
and the uterus are of epithelial origin, i.e.
carcinomas. The epithelia of these three
organs have a common embryological back-
ground and contain cells that have the po-
tential to differentiate along the same
Müllerian pathways (Kaufman, 1992;
Salazar et al., 1995). Thus, similar histo-
logical types of carcinoma, including se-
rous, endometrioid and mucinous carcino-
mas, are found in these organs. Serous car-
cinoma is the predominant histological type
in the ovary and the fallopian tube, whereas
in the endometrium it is the second most
common type (Kurman, 1994). The over-
all outcome in cases of endometrial carci-
noma is relatively good due to early detec-
tion of the disease (Creasman et al., 2001).
In contrast, ovarian and fallopian tube car-
cinomas carry poor prognosis, which is re-
lated to delay in detection, leading to ad-
vanced stages at diagnosis (Heintz et al.,
2001a; Heintz et al., 2001b). Traditionally,
classification and treatment of gynecologi-
cal carcinomas has been based on the organ
of origin. However, various histological
types of carcinoma in these organs differ in
respect to their associated risk factors and
biological behavior (Bokhman, 1983;
Omura et al., 1991; Risch et al., 1996).
Knowledge of the genetic and molecu-
lar alterations in gynecological carcinomas
is needed for better understanding of the
biology of the diseases and improvement
of classification and treatment modalities.
Evidence of distinct molecular back-
grounds exists for different histological
types of carcinoma in these organs, but
most of the previous literature has covered
various histological types together. In re-
cent years, introduction of genome-wide
screening techniques and array-based
methods has facilitated identification of
chromosomal and molecular alterations in
solid tumors. The aim of this thesis was to
characterize chromosomal and molecular
changes in endometrial, fallopian tube and
ovarian carcinomas, with emphasis on the
serous histological type, and to evaluate
associations between genetic changes, clini-




Review of the literature
1. Clinical and histopathological
characteristics
1.1. Embryological origin
There is a common embryological back-
ground for the ovarian surface epithelium
and the epithelial lining of fallopian tubes,
endometrium and endocervix. During em-
bryonic development coelomic epithelium
invaginates lateral to the gonadal ridge to
form the Müllerian duct system. Müllerian
ducts differentiate later to the fallopian
tubes, the uterus and the upper part of the
vagina. The ovary is covered by coelomic
mesothelium which overlies the gonadal
ridge (Salazar et al., 1995). In the mouse,
it has been shown that in addition to this
coelomic covering, the ovaries are envel-
oped later by Müllerian ducts (Kaufman,
1992). Thus, ovarian surface epithelium
is of common origin with epithelia of the
fallopian tubes and endometrium, due to
a common coelomic or Müllerian back-
ground. In adult women, the epithelia of
these organs contain cells that have the
potential to differentiate along distinct
Müllerian pathways and to develop into
serous, endometrioid and mucinous tu-
mors resembling epithelia of the fallopian
tube, uterus and endocervix (Salazar et al.,
1995).
1.2. Ovarian carcinoma
In Finland, 580 new cases of ovarian cancer
were diagnosed in 1998. The age-standard-
ized incidence was 13.3 per 100 000 per-
son-years (adjusted for age to the “world
standard population”) (The Finnish Cancer
Registry; http://www.cancerregistry.fi). The
mean age at diagnosis is 62 years (Dickman
et al., 1999). Epithelial ovarian cancer ac-
counts for approximately 90% of ovarian
malignancies. The most common histologi-
cal type of ovarian carcinoma is serous, com-
prising over 50% of the cases. Mucinous and
endometrioid types account for approxi-
mately 15% each. Less frequent histologi-
cal types of ovarian carcinoma include clear
cell carcinoma, undifferentiated carcinoma,
malignant mixed epithelial tumor and ma-
lignant Brenner tumor (Kurman, 1994;
Heintz et al., 2001b).
Multiparity, lactation, use of oral contra-
ceptives, tubal ligation and hysterectomy
are associated with a decreased risk of ova-
rian cancer (Whittemore et al., 1992;
Hankinson et al., 1993). The risk factors
have been reported to differ between histo-
logical subtypes: for example, the protec-
tive effects of parity and oral contraceptives
appear not to involve mucinous carcinoma
(Kvale et al., 1988; Risch et al., 1996). It
has been estimated that about 5–10% of
ovarian carcinomas are related to inherited
predisposition. Known cancer-predisposing
syndromes that are linked to ovarian carci-
noma include breast and ovarian cancer syn-
drome (BRCA1/BRCA2 genes) and heredi-
tary non-polyposis colorectal cancer
(HNPCC) syndrome (Boyd and Rubin,
1997).
The prognosis of ovarian carcinoma is
poor, reflecting the frequent finding of ad-
vanced disease at diagnosis. The five-year
overall survival rate is 48%, varying from
85% at stage I to 17% at stage IV (Heintz
et al., 2001b). Mucinous carcinoma is asso-
ciated with the best five-year survival rate
(69%), whereas for serous and endometrioid
carcinomas the rates are 40% and 60%, re-
spectively (Heintz et al., 2001b). Compared
with other histological types, it is typical
of mucinous carcinoma to be associated with
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a better prognosis at a low stage, but a worse
prognosis in high stage disease (Omura et
al., 1991; Vergote et al., 1993; Makar et
al., 1995). Clear cell carcinoma is associ-
ated with the worst prognosis at all stages.
In addition to FIGO stage and histological
type, prognostic factors in ovarian carci-
noma include histological grade, residual
disease, performance status and age (Fried-
lander, 1998).
1.3. Endometrial carcinoma
In 1998, 738 new cases of uterine cancer
were diagnosed in Finland. The age-stan-
dardized incidence was 15.5 per 100 000
person-years (adjusted for age to the “world
standard population”) (The Finnish Cancer
Registry). Most patients are postmenopausal
and the mean age at diagnosis is 66 years
(Dickman et al., 1999). Epithelial malig-
nancies represent over 90% of uterine can-
cers. Almost all of these are adenocarcino-
mas, and the most frequent histological type
is endometrioid, seen in over 80% of cases.
Serous carcinoma accounts for 5–10% of en-
dometrial carcinomas. Other histological
types include clear cell and mucinous. Foci
of squamous differentation are found in the
endometrioid, but not in the serous type
(Kurman, 1994; Creasman et al., 2001).
Based on clinicopathological observa-
tions, two different categories of endome-
trial carcinoma have been described: type I
(estrogen-dependent) and type II (estrogen-
independent) (Bokhman, 1983; Deligdisch
and Holinka, 1987). Type I tumors corre-
spond to the endometrioid type of endome-
trial carcinoma, whereas type II tumors in-
clude serous carcinomas. Most of the risk
factors for type I carcinomas are associated
with excessive estrogen, which leads to con-
tinued stimulation of the endometrium.
Risk factors for this type include obesity,
unopposed exogenous estrogen, early me-
narche and late menopause, nulliparity,
chronic anovulation, estrogen-producing
tumors, diabetes and hypertension (Smith
et al., 1975; Kelsey et al., 1982; Schwartz
et al., 1985). No clear risk factors have been
identified for type II carcinoma, which oc-
curs in an older age group than type I carci-
noma. It is frequently adjacent to atrophic
endometrium and is not associated with
hyperestrogenism (Bokhman, 1983;
Deligdisch and Holinka, 1987). The known
cancer-predisposing syndrome related to
endometrioid endometrial carcinoma is
HNPCC syndrome, which is linked to
germline DNA mismatch repair gene mu-
tations (Aarnio et al., 1995).
The majority of endometrial carcinomas
are diagnosed at an early stage and the over-
all prognosis is good. The five-year overall
survival rate is 77%, varying from 87% at
stage I to 18% at stage IV (Creasman et al.,
2001). Serous carcinomas are more advanced
at the time of diagnosis and their prognosis
tends to be worse at all stages compared
with endometrioid carcinomas (Hendrick-
son et al., 1982; Creasman et al., 2001). The
overall five-year survival rates are 54% and
80% for serous and endometrioid carcino-
mas, respectively (Creasman et al., 2001).
In addition to stage and histological type
of tumor, the histological grade, lympho-
vascular space involvement and patient age
are of prognostic value in endometrial car-
cinoma (Connelly et al., 1982; Abeler and
Kjorstad, 1991).
1.4. Fallopian tube carcinoma
Fallopian tube carcinoma is a relatively rare
malignancy, with approximately 35 to 40
new cases diagnosed annually in Finland.
In 1993–1997, the age-standardized inci-
dence was 5.4 per 1 000 000 person-years
(adjusted for age to the “world standard
population”) (The Finnish Cancer Registry).
The mean age at diagnosis is approximately
62 years (Rosen et al., 1998; Baekelandt et
al., 2000). The majority of fallopian tube
carcinomas are of serous histology (Rosen
et al., 1998; Baekelandt et al., 2000). Other
histological types include endometrioid,
Review of the Literature
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clear cell, mucinous, transitional cell and
undifferentiated carcinomas (Alvarado-
Cabrero et al., 1999; Baekelandt et al.,
2000).
The prognosis of patients with fallopian
tube carcinoma is poor. The five-year over-
all survival rate is approximately 45%
(Rosen et al., 1998; Wolfson et al., 1998;
Baekelandt et al., 2000; Heintz et al.,
2001a), varying from 73% at stage I to
12% at stage IV (Baekelandt et al., 2000).
Due to the relative rarity of the disease,
most studies have included only limited
numbers of cases. Findings concerning
prognostic factors have varied, but FIGO
stage, residual tumor size, histological
grade and closure of the fimbriated end of
the tube have shown independent prog-
nostic value (Rosen et al., 1998; Alvarado-
Cabrero et al., 1999; Baekelandt et al.,
2000).




Most of the previous studies on cytogenetic
and molecular changes in ovarian carcinoma
have involved all histological types of car-
cinoma as a single disease entity. Cytoge-
netic analyses have revealed abnormal karyo-
types in approximately 50–90% of ovarian
carcinomas (Pejovic et al., 1992a; Pejovic
et al., 1992b; Jenkins et al., 1993; Thomp-
son et al., 1994a; Taetle et al., 1999b). The
findings have varied in different studies, but
most ovarian carcinomas show complex
karyotypic changes with multiple numeri-
cal and structural aberrations. Simple
changes, i.e. numerical changes only and/
or a single structural change, are seen only
in a minority of cases. The most common
simple numerical aberration has been tri-
somy 12, which has been detected as a sole
abnormality in some cases (Yang-Feng et
al., 1991; Pejovic et al., 1992a; Pejovic et
al., 1992b; Jenkins et al., 1993; Thompson
et al., 1994b). Karyotypes with complex
aberrations frequently show chromosome
losses, deletions and unbalanced transloca-
tions, leading to loss of chromosomal ma-
terial, especially at X, 6, 8, 13, 17 and 22
(Tanaka et al., 1989; Pejovic et al., 1992a;
Jenkins et al., 1993; Thompson et al.,
1994a; Tibiletti et al., 1996). Double min-
utes and homogeneously staining regions
are also detected, indicating amplification
of DNA sequences (Tanaka et al., 1989;
McGill et al., 1993; Taetle et al., 1999b).
The chromosomes most frequently involved
as regards structural changes are 1, 3, 6, 7,
11, 12 and 19 (Tanaka et al., 1989; Pejovic
et al., 1992a; Jenkins et al., 1993; Thomp-
son et al., 1994a; Tibiletti et al., 1996;
Taetle et al., 1999b). Cytogenetic abnor-
malities and their complexity are correlated
with the grade of ovarian carcinomas
(Pejovic et al., 1992b; Taetle et al., 1999b).
In addition, cytogenetic alterations have
been found more often in the serous histo-
logical type (Pejovic et al., 1992b). Patients
with tumors showing abnormal karyotypes
have showed reduced survival times (Pejovic
et al., 1992b), and breakpoints at 1p and
3p have been shown to be independent pre-
dictors of poor prognosis (Taetle et al.,
1999a).
2.1.2. Molecular genetic changes
Aberration of the tumor suppressor gene
P53 is the most frequent molecular alter-
ation detected in ovarian carcinomas. P53
mutation and/or overexpression of P53,
which results from sequestration of mutated
protein in the nucleus, are identified in
about half of the cases of ovarian carcinoma
(Marks et al., 1991; Milner et al., 1993;
Klemi et al., 1995). P53 alterations have
been associated with serous histology
(Milner et al., 1993; Klemi et al., 1995;
Eltabbakh et al., 1997; Rohlke et al., 1997;
Anttila et al., 1999; Geisler et al., 2000),
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high tumor grade (Hartmann et al., 1994;
Henriksen et al., 1994; Klemi et al., 1995;
Eltabbakh et al., 1997; Rohlke et al., 1997;
Anttila et al., 1999; Baekelandt et al., 1999;
Levesque et al., 2000; Reles et al., 2001)
and high tumor stage (Henriksen et al.,
1994; Eltabbakh et al., 1997; Anttila et al.,
1999; Geisler et al., 2000; Levesque et al.,
2000; Fallows et al., 2001). P53-defective
ovarian carcinomas have shown resistance
to platinum-based chemotherapy (Righetti
et al., 1996; Buttitta et al., 1997; Reles et
al., 2001), but seem to respond to paclitaxel/
platinum-based therapy (Lavarino et al.,
2000). Findings concerning the prognostic
value of P53 status in ovarian carcinoma
have been inconsistent: several investigators
have reported P53 alterations to confer poor
prognosis (Hartmann et al., 1994; Henrik-
sen et al., 1994; Klemi et al., 1995;
Eltabbakh et al., 1997; Rohlke et al., 1997;
Anttila et al., 1999; Baekelandt et al., 1999;
Geisler et al., 2000; Levesque et al., 2000;
Reles et al., 2001), whereas others have not
found such an association (Marks et al.,
1991; Silvestrini et al., 1998; Gadducci et
al., 2000; Fallows et al., 2001).
Lost expression of MTS1 has been iden-
tified in 20% of ovarian carcinomas, mainly
in mucinous and endometrioid tumors
(Milde-Langosch et al., 1998). Mutations
of PTEN occur in about 20% of endo-
metrioid ovarian carcinomas, but are rare
in the serous histological type (Tashiro et
al., 1997a; Obata et al., 1998). Frequent
LOH at the RB locus (13q14) has been de-
tected in ovarian carcinomas, but no changes
in the expression of RB protein (Dodson et
al., 1994). Mutations of BRCA1 and
BRCA2 are rarely seen in sporadic ovarian
carcinomas (Merajver et al., 1995; Takahashi
et al., 1995; Takahashi et al., 1996).
Amplification or overexpression of the
ERBB2 oncogene is identified in approxi-
mately 30% of ovarian carcinomas (Slamon
et al., 1989; Berchuck et al., 1990; Zheng
et al., 1991; Singleton et al., 1994). It has
been suggested that ERBB2 activation in
ovarian carcinoma is associated with tumor
progression (Hellstrom et al., 2001). Find-
ings concerning the clinical impact of
ERBB2 activation are conflicting: some in-
vestigators have found a significant corre-
lation with prognosis, whereas others have
not confirmed this association (Slamon et
al., 1989; Berchuck et al., 1990; Singleton
et al., 1994; Medl et al., 1995). Mutations
of KRAS are detected more frequently in
mucinous (46–75%) than in serous (5–
20%) ovarian carcinomas (Enomoto et al.,
1991b; Ichikawa et al., 1994; Suzuki et al.,
2000a).
Amplification and/or overexpression of
other oncogenes observed in ovarian carci-
noma involve CMYC (29–37%) (Baker et
al., 1990; Tashiro et al., 1992), CMET
(28%) (Di Renzo et al., 1994), INT2 (19%)
(Medl et al., 1995) and AIB1 (25%) (Tan-
ner et al., 2000). Elevated levels of AKT2
activity have been detected in over 30% of
ovarian carcinomas (Yuan et al., 2000), es-
pecially in serous tumors, and mutations
of ß-catenin have been identified in 16% of
endometrioid ovarian carcinomas (Wright
et al., 1999).
Microsatellite instability (MSI), a char-
acteristic feature of deficient mismatch re-
pair, is observed in a subset of ovarian car-
cinomas (12%–17%) (Fujita et al., 1995;
King et al., 1995; Sood et al., 2001). Some
investigators have reported low frequencies
of MSI, especially in serous ovarian carci-
nomas (0%–8%) (Fujita et al., 1995; King
et al., 1995; Haas et al., 1999), whereas in
endometrioid carcinomas instability has
been seen more frequently (50%) (Fujita et
al., 1995).
Differences between various histological
types of ovarian carcinoma are also detected
as regards e.g. structural proteins. The main
cytokeratins expressed in ovarian surface
epithelium and ovarian carcinomas are 7,
8, 18 and 19 (Moll et al., 1983). In distinc-
tion to ovarian surface epithelium and se-
rous carcinoma, mucinous carcinomas ex-
press cytokeratin 20 (Moll et al., 1992). The
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ovarian surface epithelium and serous car-
cinoma express WT1, whereas it is rare in
the mucinous and endometrioid types
(Shimizu et al., 2000). On the other hand,
CA125 expression is typical of serous and
endometrioid carcinomas, but it is usually
not found in mucinous carcinomas (de la
Cuesta et al., 1999).
2.2. Endometrial carcinoma
2.2.1. Cytogenetic findings
Cytogenetic studies, involving mostly endo-
metrioid endometrial carcinomas, have re-
vealed relatively simple numerical and
structural aberrations, and the modal chro-
mosome number has been near diploid. The
most consistent finding is gain of 1q chro-
mosomal material (Fujita et al., 1985; Cou-
turier et al., 1986; Couturier et al., 1988;
Milatovich et al., 1990; Shah et al., 1994;
Bardi et al., 1995). Most of the chromo-
some 1 imbalances are rearrangements in-
volving centromeric or paracentromeric
break-points and some cases have shown
isochromosome 1q formation (Fujita et al.,
1985; Couturier et al., 1986; Shah et al.,
1994). Other frequent findings include tri-
somy of chromosomes 10, 7 and 12 (Cou-
turier et al., 1986; Couturier et al., 1988;
Simon et al., 1990; Shah et al., 1994; Bardi
et al., 1995). One study showed deletion of
distal 6q as the most common finding
(Tibiletti et al., 1997). Four cases of serous
endometrial carcinomas have been included
in cytogenetic analyses. One showed no
changes, one was not analyzable and two
presented with multiple complex changes
and intratumor heterogeneity distinct from
changes in endometrioid carcinomas (Bardi
et al., 1995; Tibiletti et al., 1997).
2.2.2. Molecular genetic changes
During the years when this study was per-
formed, new information about the molecu-
lar genetic background of endometrioid
endometrial carcinoma has emerged. Fre-
quent allelic loss at 10q23-q26 was detected
in endometrial carcinomas (Peiffer et al.,
1995). Subsequently, a putative tumor sup-
pressor gene PTEN was identified at
10q23.3 (Li et al., 1997; Steck et al., 1997)
and frequent mutations of this gene (34%–
50%) were found in endometrioid endome-
trial carcinomas (Kong et al., 1997;
Risinger et al., 1997; Tashiro et al., 1997a).
Mutations were also described in about
20%–30% of endometrial hyperplasias, the
putative precursor lesions of endometrioid
carcinoma (Levine et al., 1998; Maxwell et
al., 1998). Furthermore, histologically nor-
mal premenopausal endometria were found
to contain occasional glands that failed to
express PTEN protein because of mutation
and/or deletion (Mutter et al., 2001). Thus,
loss of PTEN expression seems to occur early
in the pathogenesis of endometrial adeno-
carcinoma.
Microsatellite instability (MSI) is fre-
quent in endometrial tumors associated
with HNPCC (Risinger et al., 1993) and is
due to germline mutations in mismatch
repair genes. MSI is detected in approxi-
mately 20% of sporadic endometrioid en-
dometrial carcinomas (Risinger et al., 1993;
Burks et al., 1994; Duggan et al., 1994a;
Kobayashi et al., 1995; Peiffer et al., 1995;
Caduff et al., 1996), but mutations of the
known mismatch repair genes are rarely
observed (Katabuchi et al., 1995; Kowalski
et al., 1997; Gurin et al., 1999). Recent
studies have suggested that deficient mis-
match repair in sporadic endometrial carci-
nomas may result from inactivation of
MLH1 due to promoter hypermethylation
of the gene (Esteller et al., 1998; Gurin et
al., 1999; Simpkins et al., 1999; Salvesen
et al., 2000). Both MSI and MLH1 pro-
moter hypermethylation have been detected
in complex hyperplasias with coexisting
endometrial adenocarcinoma, but not in
normal endometrium (Mutter et al., 1996;
Esteller et al., 1999).
Mutations of the KRAS oncogene are
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identified in approximately 20% of endo-
metrioid endometrial carcinomas (Enomoto
et al., 1991a; Sasaki et al., 1993; Duggan
et al., 1994b; Caduff et al., 1995; Lax et
al., 2000). KRAS mutations are also found
in cases of endometrial hyperplasia, and
mutations are not associated with grade or
stage of endometrial carcinomas, suggest-
ing that KRAS mutation may represent an
early event in a subset of endometrial carci-
nomas. Overexpression and mutations of
P53 are detected in about 20% of cases of
endometrioid endometrial carcinoma
(Kohler et al., 1992; Zheng et al., 1996;
Lax et al., 2000). Alterations of P53 are as-
sociated with high tumor grade and stage
and they are not seen in endometrial hyper-
plasia (Kohler et al., 1992; Zheng et al.,
1996; Lax et al., 2000), suggesting that P53
mutations in endometrioid carcinoma are
related to progression rather than tumor
initiation. Amplification and overexpression
of the ERBB2 oncogene has been detected
in a subset of endometrial carcinomas and
it has been associated with high tumor grade
and poor overall survival (Saffari et al., 1995;
Rolitsky et al., 1999).
In contrast to the endometrioid histologi-
cal type, serous endometrial carcinoma pre-
sents with frequent P53 alterations (90%),
which are observed with similar frequency
in cases of endometrial intraepithelial car-
cinoma (EIC), the putative precursor of se-
rous carcinoma (Sherman et al., 1995; Moll
et al., 1996; Zheng et al., 1996; Tashiro et
al., 1997b; Lax et al., 2000). However,
PTEN and KRAS mutations and MSI are
rarely identified in serous endometrial car-
cinomas (Duggan et al., 1994a; Duggan et
al., 1994b; Caduff et al., 1995; Tashiro et
al., 1997a; Tashiro et al., 1997c; Lax et al.,
2000). An association between ERBB2
amplification and serous rather than endo-
metrioid histological type has also been re-
ported (Rolitsky et al., 1999). Most serous
endometrial carcinomas are negative for es-
trogen and progesterone receptors
(Umpierre et al., 1994; Moll et al., 1996),
in contrast to endometrioid endometrial
carcinomas, particularly those of low grade,
which show hormone receptor positivity
(Nyholm et al., 1992).
2.3. Fallopian tube carcinoma
Few investigations have been carried out on
the genetic background of fallopian tube
carcinoma, and its pathogenesis is poorly
understood. Complex karyotypic abnor-
malities were reported in cytogenetic analy-
sis of one case of fallopian tube carcinoma
(Bardi et al., 1994). Overexpression and
mutations of P53 are detected in approxi-
mately 60% of cases of fallopian tube carci-
noma (Lacy et al., 1995; Runnebaum et al.,
1996; Zheng et al., 1997; Chung et al.,
2000). Alterations of P53 are seen at all
stages of tumors with similar frequency,
including in situ carcinomas (Zheng et al.,
1997; Demopoulos et al., 2001), and the
frequency of P53 alterations is higher in
serous than in other histological types
(Zheng et al., 1997). One group reported
an association between P53 alterations and
poor clinical outcome (Zheng et al., 1997),
but others have not found correlations with
clinicopathological parameters (Lacy et al.,
1995; Chung et al., 2000; Demopoulos et
al., 2001). Mutations of the KRAS oncogene
and overexpression of ERBB2 protein, but
no amplification of the gene, have been ob-
served in fallopian tube carcinomas (Lacy
et al., 1995; Mizuuchi et al., 1995;
Stuhlinger et al., 1995; Chung et al., 2000).
3. Overview of comparative genomic
hybridization (CGH)
3.1. Methodology
Comparative genomic hybridization, intro-
duced in 1992, is based on simultaneous
hybridization of differentially labeled tumor
and normal DNAs on normal metaphase
chromosomes (Kallioniemi et al., 1992;
Kallioniemi et al., 1994). Analysis of the
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ratio of the test and control fluorescence
intensities provides an indication of the
DNA sequence copy number changes
throughout the tumor genome in a single
experimental setting (Figure 1). The fluo-
rescence intensity ratios are measured us-
ing a digital image analysis system. Ratios
that are increased or decreased compared
with the normal ratio reveal gains and losses
of DNA sequences in the test sample.
Gained or amplified regions of the tumor
genome are thought to contain oncogenes,
whereas losses are thought indicate locations
of tumor suppressor genes.
The main advantage of CGH compared
with traditional cytogenetics is that no cul-
turing of the tumor sample is needed. This
makes CGH especially suitable for analysis
of copy number changes in solid tumors,
where high quality metaphase preparations
are often difficult to make. Furthermore,
solid tumors often show complex karyo-
types, which are laborious and sometimes
impossible to interpret. However, CGH
cannot detect balanced translocations, in-
versions or ploidy changes. The sensitivity
of the method depends on the size and the
magnitude of the copy number aberration
(Kallioniemi et al., 1994). If the sequence
is highly amplified (5–10-fold), copy num-
ber increases as small as 1 Mb can be de-
tected, whereas deletions of less than 10 Mb
are unlikely to be seen (Forozan et al., 1997;
Bentz et al., 1998). Some genomic areas,
such as pericentromeric and heterochro-
matic regions, contain highly repetitive se-
quences and are blocked by unlabeled Cot-
1 DNA and thus cannot be reliably ana-
lyzed. Ratio changes in the telomeric re-
gions should be interpreted with caution
because fluorescence intensities decrease to-
wards the telomeres, approaching the back-
ground fluorescence, and therefore unreli-
able results may be obtained (Kallioniemi
et al., 1994). Direct fluorochrome-conju-
gated nucleotides have replaced the indi-
rect labeling system, which has improved
the sensitivity of the method (Kallioniemi
et al., 1994). Ratio artefacts, which may
occur in CG-rich genomic areas, can be
minimized by using a mixture of dCTP and
dUTP nucleotides in the labeling procedure
(El-Rifai et al., 1997). Degenerate oligo-
nucleotide-primed PCR has enabled the use
of very small amounts of DNA (Speicher et
al., 1993; Kuukasjarvi et al., 1997).
3.2. CGH studies
3.2.1. Ovarian carcinoma
So far, at least 13 studies, covering over 400
cases of primary ovarian carcinoma have
been published (Iwabuchi et al., 1995;
Arnold et al., 1996; Sonoda et al., 1997b;
Tapper et al., 1997; Wolff et al., 1997; Tap-













Figure 1. The principle of comparative genomic
hybridization (CGH). Differentially labeled tumor
and normal DNAs are hybridized together with
Cot-1 DNA to normal metaphase chromosomes.
Separate images are captured for counterstain
(DAPI), tumor DNA (FITC, green) and normal
DNA (TRITC, red). Differences in the tumor to
normal fluorescence intensity ratio on the chro-
mosomes reflect DNA copy number changes in
the tumor sample. The ratio is calculated as CGH
profile.
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et al., 1999; Blegen et al., 2000; Patael-
Karasik et al., 2000; Suzuki et al., 2000b;
Kiechle et al., 2001; Shridhar et al., 2001).
In these studies approximately 60% of the
carcinomas were of serous histology. Chro-
mosomal changes observed in ovarian car-
cinomas were generally frequent and com-
plex (Table 1). Copy number alterations
were found in approximately 95% of ova-
rian carcinomas and the average number of
aberrations per tumor varied from 4.0 to
20.
In a previous study by our group, serous,
mucinous and endometrioid ovarian carci-
nomas were analyzed separately, and distinct
genomic aberrations in the different histo-
logical types were found (Tapper et al.,
1997). Serous carcinomas showed more
chromosomal alterations than mucinous and
endometrioid carcinomas, the average num-
ber of changes being 7.5 for serous, 4.4 for
mucinous and 4.5 for endometrioid carci-
nomas. Gains at 1q occurred only in serous
and endometrioid carcinomas, whereas an
increased copy number of 17q was mostly
seen in mucinous tumors. Overrepresen-
tation of 11q was typical of serous carci-
noma and gain at 10q was typical of muci-
nous carcinoma.
3.2.2. Endometrial carcinoma
Since the introduction of CGH, 86 cases of
endometrial carcinoma have been analyzed
by this method fu (Sonoda et al., 1997a;
Suzuki et al., 1997; Suehiro et al., 2000;
Baloglu et al., 2001) (Table 1). In these stud-
ies over 90% of the cases have been of endo-
metrioid histological type. Chromosomal
aberrations were seen in 73% of the tumors
and the average number of chromosomal
changes detected per tumor varied from 3.4
to 5.7.
3.2.3. Fallopian tube carcinoma
Previously, a single CGH study of fallo-
pian tube carcinoma has been published
(Heselmeyer et al., 1998). It showed copy
number alterations in all 12 carcinomas and
the average number of aberrations per tu-
mor was 19.7. Gains at chromosome arms
3q and 1q were seen in 11 of the 12 tu-
mors. Other frequent overrepresentations
were located at 2q, 7q, 8q, 5p, 6p, 12p and
14q (>50% of the cases). The most recur-
rent regions of underrepresentation were at






































































Ovarian carcinoma Endometrial carcinoma
Table 1. The most frequent copy number changes detected by CGH in 405 ovarian carcinomas (Iwabuchi
et al., 1995; Arnold et al., 1996; Sonoda et al., 1997b; Tapper et al., 1997; Wolff et al., 1997; Tapper et
al., 1998; Kudoh et al., 1999; Pejovic et al., 1999; Blegen et al., 2000; Patael-Karasik et al., 2000; Kiechle
et al., 2001; Shridhar et al., 2001) and 86 endometrial carcinomas (Sonoda et al., 1997a; Suzuki et al.,
1997; Suehiro et al., 2000; Baloglu et al., 2001).
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4. Overview of allelic analysis
4.1. Loss of heterozygosity (LOH)
According to the classical two-hit model,
inactivation of both alleles of a tumor sup-
pressor gene is needed for cancer formation
(Knudson, 1971). One allele is usually in-
activated by mutation, either somatic or
inherited (Figure 2). The other allele can
be inactivated by various mechanisms, such
as loss of the whole or part of a chromo-
some, loss of the normal chromosome and
reduplication of the mutated one, gene con-
version, mitotic recombination, point mu-
tation, deletion or epigenetic mechanism,
such as promoter hypermethylation
(Knudson, 1971; Cavenee et al., 1983;
Esteller et al., 2000). In LOH analysis, also
called allele analysis or allelotyping, the loss
of one allele of a tumor suppressor gene can
be observed as loss of heterozygosity of in-
tragenic or nearby polymorphic markers in
tumor tissue compared with normal tissue
from the same individual. Thus, regions of
the genome showing frequent LOH are
thought to contain tumor suppressor genes.
To analyze LOH, restriction fragment
length polymorphisms (RFLPs) and South-
ern blotting were used initially. Introduc-
tion of polymorphic microsatellite markers
and PCR-based amplification facilitated
Somatic
mutation Deletion
Normal tissue Tumor tissue Tumor tissue Assessment of LOH
Figure 2. The principle of loss of heterozygosity (LOH) in a sporadic tumor. One allele of the gene is
inactivated by mutation and the other allele by deletion. In allelic analysis the deletion is seen as loss of
one allele of the microsatellite marker. Upper lane, amplification from normal DNA. Lower lane, ampli-
fication from tumor DNA.
allelic analyses by consuming less time and
DNA, and by increasing resolution (Weber
and May, 1989). Further improvement was
made by way of fluorescence-labeled prim-
ers and computer-based measurement of
sizes and intensities of alleles (Ziegle et al.,
1992; Reed et al., 1994). Comparisons of
radiographic and fluorescence-based meth-
ods have shown high concordance between
the findings (Schwengel et al., 1994;
Canzian et al., 1996). The main advantages
of semiautomated fluorescence-based
allelotyping are possibility of multiplexing
loci and objective scoring of alleles.
4.2. LOH in ovarian carcinoma
4.2.1. Genome-wide analyses
In ovarian carcinoma several LOH studies
have been performed, and allelic loss has
been found in all chromosomes at varying
frequencies. Studies in which the whole
genome has been screened, with one or a
few loci per chromosome arm, showed fre-
quent losses at 5q, 6p, 6q, 9q, 13q, 17p,
17q, 18q, 19p, 22q and Xp (Sato et al.,
1991; Cliby et al., 1993; Dodson et al.,
1993; Yang-Feng et al., 1993; Osborne and
Leech, 1994). These regions showed allelic
loss in over 30% of informative cases and
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the highest frequency of LOH, over 50% of
informative cases, was observed at chromo-
some 17. In addition to these regions, stud-
ies concentrating on specific chromosomes
have shown frequent allelic losses at 1p, 2q,
3p, 7q, 8p, 9p, 11p, 11q, 14q and 16q
(Zheng et al., 1991; Weitzel et al., 1994;
Gabra et al., 1996; Bandera et al., 1997;
Edelson et al., 1997; Lu et al., 1997;
Saretzki et al., 1997; Lounis et al., 1998;
Wright et al., 1998; Fullwood et al., 1999;
Huang et al., 1999; Imyanitov et al., 1999;
Launonen et al., 2000).
Differences in the frequency and pattern
of LOH have been observed in different his-
tological types of ovarian carcinoma. Serous
carcinomas display a higher overall fre-
quency of allelic loss than non-serous his-
tological types (Sato et al., 1991; Cliby et
al., 1993; Saretzki et al., 1997). Specific
chromosomal arms that show a higher fre-
quency of LOH in serous than in non-se-
rous tumors, especially mucinous carcino-
mas, include 6q, 13q, 11p, 11q, 17p, 17q,
19q and 22q (Sato et al., 1991; Saito et al.,
1992; Foulkes et al., 1993; Orphanos et al.,
1995; Pieretti et al., 1995; Papp et al.,
1996; Lu et al., 1997; Bryan et al., 2000;
Garcia et al., 2000; Launonen et al., 2000;
Suzuki et al., 2000a). On the other hand,
losses at 9p have been seen more frequently
in mucinous than in serous carcinomas
(Watson et al., 1998).
The total number of allelic losses in ova-
rian carcinoma has been associated with
tumor grade and patient survival (Zheng et
al., 1991; Cliby et al., 1993; Dodson et al.,
1993; Saretzki et al., 1997). Losses at chro-
mosomes 3 and 11 and chromosome arms
6q, 13q and 15q have been associated with
high tumor grade (Zheng et al., 1991;
Dodson et al., 1993; Foulkes et al., 1993;
Kim et al., 1994), whereas losses at 3p and
16q have been correlated with high tumor
stage (Fullwood et al., 1999; Launonen et
al., 2000). Poor patient survival has been
observed in association with tumors show-
ing LOH at chromosomes 11 (11p15.5 and
11q23.3-q24.3) and 17 (Gabra et al., 1996;
Chenevix-Trench et al., 1997; Launonen et
al., 2000).
4.2.2. Chromosome arm 8p
In LOH studies involving all chromosomal
arms in ovarian carcinoma, allelic loss at 8p
was found in 23% to 40% of the cases (Cliby
et al., 1993; Dodson et al., 1993; Yang-Feng
et al., 1993; Osborne and Leech, 1994).
Studies in which mapping of 8p was per-
formed with several markers showed LOH
at a frequency of 50–78% (Wright et al.,
1998; Brown et al., 1999; Pribill et al.,
2001). Allelic loss at this chromosomal arm
has been associated with high tumor grade
(Dodson et al., 1993; Pribill et al., 2001)
and high tumor stage (Wright et al., 1998;
Brown et al., 1999; Pribill et al., 2001). In
these studies no association between LOH
at 8p and histological type of tumor was
observed. Wright et al. defined three regions
of overlap, two at 8p23 and one at 8p22
(Wright et al., 1998). Brown et al. found
the highest frequency of allelic loss at
marker D8S136 (8p21) (Brown et al.,
1999). Pribill et al. found three smallest
regions of overlap: one at 8p22, one at 8p21
and one at 8p12-21 (Pribill et al., 2001).
The minimal common regions of LOH de-
fined in these three studies (Wright et al.,
1998; Brown et al., 1999; Pribill et al.,
2001) are discussed in more detail in the
Discussion.
4.2.3. Chromosome arm 18q
Studies of ovarian carcinoma in which the
whole genome was screened, with one or a
few loci per chromosome arm, the long arm
of chromosome 18 showed allelic loss at a
frequency varying from 0% to 47% of cases
(Sato et al., 1991; Cliby et al., 1993;
Dodson et al., 1993; Yang-Feng et al.,
1993; Osborne and Leech, 1994). However,
investigators using several microsatellite
markers at 18q have observed higher fre-
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quencies of LOH, ranging from 41% to
60% (Chenevix-Trench et al., 1992;
Takakura et al., 1999). The highest frequen-
cies of allelic loss have been detected distal
to 18q21 (Chenevix-Trench et al., 1992;
Zborovskaya et al., 1999). LOH at this
chromosomal arm has been found to be as-
sociated with high stage ovarian carcino-
mas (Chenevix-Trench et al., 1992;
Zborovskaya et al., 1999).
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Aims of the study
The aims of the present study were:
1. to identify copy number changes in endometrial and fallopian tube carcinomas (I, II)
2. to compare the copy number karyotypes of serous and endometrioid endometrial
carcinomas (I)
3. to compare the copy number karyotypes of serous carcinomas of the fallopian tube,
endometrium and ovary (II)
4. to compare the allelotypes of serous and mucinous ovarian carcinomas at chromo-
some arms 8p and 18q (III, IV)
5. to define the putative tumor suppressor locus/loci more precisely at 8p21-p23 and
18q12.3-q23 by allelic analysis in serous ovarian carcinoma (III, IV)
6. to compare genomic and molecular aberrations with histopathological parameters




1. Clinical material (I–V)
Tumor samples were obtained from patients
undergoing primary surgery for gynecologi-
cal carcinomas at the Department of Ob-
stetrics and Gynecology, Helsinki Univer-
sity Central Hospital (Table 2). The studies
were approved by the Ethics Committee of
the Department of Obstetrics and Gynecol-
ogy. Informed consent was obtained from
the patients in regard to blood samples and
fresh tumor material.
All the tumor specimens in a particular
study were reviewed by the same investiga-
tor as regards histological subtype and grade
(I: Torsten Wahlström; II–V: Ralf Bützow).
Tumor stage and other clinical information
on the patients was extracted from the medi-
cal records of the Department of Obstetrics
and Gynecology (I–V). Additional survival
information was obtained from the Popu-
lation Register Center of Finland. In study
I, cases of endometrioid endometrial carci-
nomas were selected to match the stage of
the serous endometrial carcinomas.
2. Methods
2.1. Comparative genomic hybridization (I, II)
Genomic DNA from frozen tissues and
leucocytes of healthy women, which was
used as normal reference DNA in the hy-
bridizations and for negative control experi-
ments, was extracted by using standard
methods. DNA from paraffin-embedded
tissues was extracted according to the pro-
tocol described by Isola et al. (Isola et al.,
1994). Metaphase slides were prepared from
phytohemagglutinin-stimulated peripheral
blood lymphocytes from healthy individu-





75 serous OC and blood samples






34 normal ovarian samples
23 normal fallopian tube samples
Sample typea
22 paraffin, 2 frozen
paraffin










(no. of tumor samples)
I (24), II (24)
I (24)
II (20)
III (62), IV (64)
III (14), IV (9)
III (33)
III (26)
















Table 2. Samples and methods.
EC = endometrial carcinoma; FTC = fallopian tube carcinoma; OC = ovarian carcinoma; a paraffin = paraffin embedded
sample; frozen = fresh frozen sample; CGH = comparative genomic hybridization; LOH = allelic analysis;
MD = microdissection; NB = Northern blot; ICH = immunohistochemistry
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Comparative genomic hybridization was
performed as described previously (Kallio-
niemi et al., 1992; Kallioniemi et al., 1994)
and a protocol involving directly fluoro-
chrome-conjugated nucleotides was fol-
lowed, with some modifications (El-Rifai
et al., 1997). Tumor DNA was labeled with
FITC-12-dUTP or a mixture of FITC-12-
dUTP and FITC-12-dCTP (1:1; DuPont,
Boston, MA, USA). The reference DNA was
conjugated to Texas Red-5-dUTP or a mix-
ture of Texas Red-5-dUTP and Texas Red-
5-dCTP (1:1; DuPont). DNA was labeled
using a standard nick-translation reaction,
and the reaction was optimized to produce
DNA fragments of 600 to 2000 bp in
length. One µg of labeled tumor and nor-
mal female DNA, as well as 20 µg of unla-
beled human Cot-1 DNA (Gibco BRL,
Gaithersburg, MD), were precipitated in 1/
10 volume of 3 M sodium acetate (pH 6.0)
and 3 volumes of absolute ethanol at -20
°C overnight and dissolved in 10 µl of hy-
bridization buffer (50% formamide/ 10%
dextran sulfate/ 2× SSC, pH 7.0) at 37 °C.
Metaphase preparations were pretreated in
2× SSC at 40 °C for 30 min, and dehydrated
in a series of 70%, 85% and 100% ethanol.
The preparations were then denatured in
formamide solution (70% formamide/ 2×
SSC, pH 7.0) at 62–66 °C for 2 min, dehy-
drated in an ethanol series on ice, treated
with proteinase K (0.1–0.2 µg/ml in 20 mM
Tris-HCl, 2 mM CaCl
2
, pH 7.6) and dehy-
drated in an ethanol series. The DNA probe
mixture was denatured at 75 °C for 5 min
just before application to the metaphase
preparation. Hybridization was carried out
in a moist chamber at 37 °C for 2–3 days.
After hybridization, the preparations were
washed to remove unbound DNA: three
times in 50% formamide/ 2× SSC, pH 7.0,
twice in 2× SSC and once in 0.1× SSC at 45
°C for 10 min each, followed by washes in









, 0.1% Nonidet P-40, pH 8.0)
and distilled water at room temperature for
10 min each. The preparations were subse-
quently stained with 4,6-diamino-2-
phenylindole (DAPI) and covered with
antifade solution (VectashieldTM, Vector
Laboratories, Burlingame, CA, USA).
Analysis was performed using a Leitz or
an Olympus fluorescence microscope con-
nected to a non-cooled CCD camera and
an ISIS digital image analysis system
(MetaSystems GmbH, Altlussheim, Ger-
many). Three-color images were captured,
green (FITC) and red (Texas Red) for the
tumor and reference DNA, respectively, and
blue (DAPI) for the counterstain on the
chromosomes. Several metaphase images
were captured, after which approximately
10 were karyotyped on the basis of the chro-
mosome banding pattern obtained by means
of the DAPI staining. Signal intensity ra-
tios of green to red along all chromosomes
were calculated for the karyotyped meta-
phases. Data from individual chromosome
homologues were combined and the mean
green to red ratio profile for each chromo-
some was displayed adjacent to chromosome
ideograms. Cut-off values were set at 0.85
and 1.17, and all the findings were con-
firmed using a confidence interval of 99%.
The chromosomal regions with a green to
red ratio under 0.85 were considered to be
underrepresented (showing loss), whereas
the regions with a ratio above 1.17 were
considered to be overrepresented (showing
gain). The cut-off values were set on the
basis of negative control experiments where
two differently labeled normal DNAs were
hybridized together. Tumor DNA with
known copy number alterations was used
in positive control experiments. The cut-
off value for high-level amplification was
1.5. Telomeric and heterochromatic regions
were excluded from the analysis. In study
I, reverse labeling CGH was performed on
three samples, which confirmed the alter-
ations detected by the standard technique.
2.2. Laser microdissection (III, IV)




scribed previously (Schutze and Lahr, 1998),
using a Robot-MicroBeam (PALM,
Wolfratshausen, Germany). Five-µm frozen
sections of mucinous ovarian carcinomas
were mounted onto slides covered with
polyethylene membrane (PALM) and poly-
L-lysine. The Robot-MicroBeam consists of
a pulsed, low-energy nitrogen laser and a
computer-controlled microscope. Selected
carcinoma cell areas were circumscribed
with the laser in order to isolate them from
surrounding normal cells. In cases in which
the selected area contained non-tumor cells,
these were eliminated by directed laser
shots. The isolated target specimens were
collected with forceps into tubes contain-
ing proteinase K buffer and DNA was ex-
tracted using a proteinase K-phenol-chlo-
roform method.
2.3. Loss of heterozygosity analysis (III, IV)
In mucinous carcinomas, as a rule the
amount of non-neoplastic cells was high and
the laser microbeam microdissection tech-
nique was used to separate carcinoma cells
before DNA extraction. In serous carci-
noma, only tissue samples with more than
40–50% of cells representing tumor cells
were included in the studies (range 40–
95%; median 70%), and no microdissec-
tion was needed. Tumor DNA was extracted
from fresh frozen tumor samples and nor-
mal DNA from blood lymphocytes of these
patients. A standard proteinase K-phenol-
chloroform method was used for DNA ex-
traction.
In order to study LOH at 8p and 18q,
sets of 18 and 27 highly polymorphic mic-
rosatellite markers at 8p21-p23 and
18q12.3-q23, respectively, were used.
Primer sequences and reaction conditions
for dinucleotide markers were obtained
from the Genethon human linkage map
(http://ftp.genethon.fr), and for tri- and
tetranucleotide markers, from Genome Da-
tabase (http://gdbwww.gdb.org). The ge-
netic order of the markers was based on the
Genethon map, the Genome Database and
GeneMap’99 (http://www.ncbi.nlm.nih.gov/
genemap/). The oligonucleotides were la-
beled fluorescently with one of three dyes
(6-FAM, TET or HEX; Institute of Biotech-
nology, University of Helsinki, Finland). A
fourth dye (TAMRA; Perkin-Elmer, Foster
City, CA) was reserved for the size standard.
The PCR reactions for genotyping were
carried out in a volume of 10 µl and included
GeneAmp 1× PCR buffer (Perkin-Elmer),
each dNTP at 50 µmol/l, 60 ng DNA (5–
10 ng DNA from the microdissected
samples), 0.5 U AmpliTaq Gold polymerase
(Perkin-Elmer) and 5 pmol of each primer
(one of them fluorescently labeled). The re-
action mixtures were given 30–35 cycles of
5 s at 96 °C, 59 s at 92 °C, 1 min 15 s at
55 °C (60 °C for D18S474, D18S815,
D18S844 and D18S845) and 45 s at 72 °C,
preceded by a 10-min hot start at 96 °C for
enzyme activation and followed by final ex-
tension at 72 °C for 30 min.
The products were pooled in groups for
electrophoresis. Each group consisted of nine
markers and the mix included 1 µl of each
PCR product. One µl of this mixture was
added to 12.5 µl formamide and 0.5 µl
TAMRA 500 size standard and it was dena-
tured at 96 °C for 3 min before loading the
samples into an ABI Prism 310 Genetic
Analyzer (Perkin-Elmer), which uses poly-
mer-filled capillary for electrophoresis.
Analysis of raw data and assessment of
LOH were performed with GeneScan and
Genotyper software (Perkin-Elmer). The
peaks of the normal DNA sample were used
to determine whether the sample was ho-
mozygous (one peak only) or heterozygous
(two peaks). If the normal DNA sample was
heterozygous as regards a given marker, the
marker was informative for LOH analysis.
The sizes of the allele peaks were assigned
according to the area under the highest peak.
When two alleles were present in normal
tissue and one was absent in the tumor, the
result was determined to be LOH. In cases
where the assessment was not clear-cut, the
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ratio of alleles was calculated for each nor-
mal and tumor sample, and the tumor ratio
was divided by the normal ratio, i.e. T2:T1/
N2:N1 (T1 and N1 are the area values for
the shorter length alleles and T2 and N2
are the values for the longer length alleles,
for tumor and normal tissue respectively).
If the ratio was <0.6 or >1.67, the result
was determined to be LOH (Canzian et al.,
1996). In ambiguous cases, the PCR was
repeated and electrophoresis was performed
without pooling.
2.4. Tumor tissue microarrays (III–V)
The tissue microarrays were constructed as
described previously (Kononen et al., 1998).
A representative tumor area was selected
from hematoxylin-eosin-stained sections of
each tumor. Core tissue biopsy specimens
(diameter 0.8 mm) were taken from these
areas of individual donor blocks and pre-
cisely arrayed into a new recipient paraffin
block with a custom-built instrument
(Beecher Instruments, Silver Spring, MD).
Four core tissue biopsies were obtained from
each carcinoma specimen. After the block
construction was completed, 5-µm sections
were cut with a microtome. The presence
of tumor tissue in the arrayed samples was
verified on hematoxylin-eosin-stained sec-
tions.
2.5. Immunohistochemistry (III–V)
Primary antibodies used for immunohis-
tochemistry were: goat polyclonal anti-
mouse GATA-4 IgG (final concentration 1
µg/ml; sc-1237, Santa Cruz Biotechnology
Inc., Santa Cruz, CA), mouse monoclonal
anti-human SMAD4 (2 µg/ml; sc-7966,
Santa Cruz Biotechnology Inc.), goat
polyclonal anti-human SMAD2 IgG (6 µg/
ml; sc-6200, Santa Cruz Biotechnology
Inc.), mouse monoclonal anti-human DCC
(5 µg/ml; clone G97-499, Pharmingen, San
Diego, CA) and mouse monoclonal anti-
human P53 (1:100 dilution, clone DO-7,
Dako, Glostrup, Denmark). The sections
were pretreated in a microwave oven in buff-
ered sodium citrate prior to SMAD4, DCC
and P53 immunohistochemistry. An avidin-
biotin immunoperoxidase system was used
to visualize the bound antibody. For
SMAD4 and P53, the procedure was run in
a Techmate automated machine (Peroxidase
DAB detection kit; DAKO ChemMate,
Denmark). For GATA-4, SMAD2 and
DCC, the procedure was performed manu-
ally (Vectastain Elite ABC kits, Vector
Laboratories, Burlingame, CA) and 3-
amino-9-ethylcarbazole was used as the
chromogen. The sections were counter-
stained with Mayer’s hematoxylin. Nonim-
mune goat IgG (for GATA-4 analysis) (III),
blocking of the antibody by peptide prein-
cubation (for SMAD2 analysis) (IV) or omis-
sion of the primary antibody were used for
negative controls. Normal ovarian samples
were used as positive controls for GATA-4,
SMAD2 and DCC. For SMAD4, colon car-
cinoma cell lines shown to express SMAD4
were used as positive controls. The stain-
ing patterns of each antigen in normal epi-
thelial cells of ovaries and fallopian tubes
were used as references of normal expres-
sion, and staining diverging from these in
tumor cells was considered aberrant.
2.6. Northern blot analysis (III)
RNA from ovarian carcinoma samples was
extracted and Northern blotting was per-
formed as previously described (Laitinen et
al., 2000). As probes for filter hybridiza-
tion we used human GATA-4 cDNA
(White et al., 1995) and rat glyceraldehyde-
6-phosphate dehydrogenase (GAPDH)
cDNA (Laitinen et al., 1997). The cDNAs
were labeled with [32P]-α-deoxy-CTP us-
ing Prime-a-gene kits (Promega, Madison,
WI).
2.7. Statistical analyses (I, III–V)




LOH and lost expression (III, IV) were
tested by using Fisher’s exact test, and dif-
ferences in total number of changes (I) and
allelic loss of informative markers (III, IV)
by using the nonparametric Mann-Whitney
U test. Associations between P53 status and
clinicopathological parameters (V) were
analyzed by using the Fisher’s exact and χ2
tests. The product-limit method was used
to construct survival curves and statistical
significance was tested by log-rank analy-
sis (I, IV, V). Multivariate survival analysis
was carried out by using the Cox propor-
tional hazards model (I, IV, V). P-values




1. DNA copy number changes de-
tected by CGH (I, II)
1.1. Serous endometrial carcinoma (I)
DNA sequence copy number changes were
detected in 71% (17/24) of serous endome-
trial carcinomas, with gains predominating
over losses (2.8:1). The most common copy
number increases were at 3q (50%), 8q
(33%), 1q (29%), 5p (29%), 6p (29%), 2q
(25%), 7q (21%), 11q (21%) and 19q
(21%). The minimal common regions of
gain at 3q and 8q were 3q26.1-qter and
8q23. High-level amplification was de-
tected in 25% of the tumors, and the mini-
mal common regions were 2q31 (two cases),
3q24-q26.3, 6p, 8q22-q24.1 (two cases),
15q25-qter, 18p11.2, 18q11.2-q12 and
20q13.1-qter. The most common copy
number losses were at 4q32-qter, 15qcen-
q15 and 18q22-qter (17% each).
1.2. Endometrioid endometrial carcinoma (I)
Copy number changes were observed in
50% (12/24) of endometrioid endometrial
carcinomas, with gains being more frequent
than losses (3.6:1). The most frequent copy
number gains were identified at 1q (29%),
2q24-q31 (13%) and 8q (13%). High-level
amplification was observed in 13% of the
cases (one region/sample): at 1q, 1q31 and
6p21-p23. Losses were rarely seen: two cases
showed loss at 15qcen-q15 and two cases
at 16qcen-q13, whereas other losses were
detected at separate regions.
1.3. Comparison of serous and endometrioid
endometrial carcinomas (I)
Serous endometrial carcinomas showed
more copy number alterations than endo-
metrioid carcinomas (5.7 and 1.5 alter-
ations/tumor, respectively). Half of the
endometrioid carcinomas presented with a
normal copy number karyotype, whereas
less than a third of the serous carcinomas
showed no changes according to CGH.
High-level amplification was more common
in serous than in endometrioid carcinomas
(10 and 3 amplifications, respectively). In












































































Table 3. The most common chromosomal changes detected by CGH in serous (n=24) and endometrioid
(n=24) endometrial carcinomas.
a
 chromosome arms showing gain in over 20% of serous or endometrioid carcinomas
b
 chromosome arms showing loss in over 10% of serous or endometrioid carcinomas
Heini Lassus
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tected at several chromosomal regions, in-
cluding 3q, 8q, 1q, 5p, 6p and 2q, whereas
in endometrioid carcinoma the only recur-
rent copy number increase was the gain of
the whole or large part of chromosome arm
1q. In both subtypes losses were relatively
rare, particularly in endometrioid carcinoma
(Table 3).
1.4. Clinicopathological associations in
endometrial carcinoma (I)
High-stage (stage III-IV) tumors showed
more copy number abnormalities than low-
stage (stage I-II) tumors in both serous and
endometrioid endometrial carcinomas
(mean numbers of changes: 6.9 and 3.7 for
serous tumors, and 1.7 and 1.1 for endo-
metrioid tumors, respectively). In endo-
metrioid carcinomas the number of changes
correlated with tumor grade (mean num-
bers of changes: grade 1, 0.73, grade 2, 2.2
and grade 3, 2.3), but in serous carcinomas
no such association was found.
Patients with serous endometrial carci-
nomas showing copy number changes had
poor overall survival when compared with
patients with serous carcinomas showing no
changes (RR=10.8; 95% CI 1.38–85.2). In
multivariate analysis neither stage nor num-
ber of changes were independent prognos-
tic factors. In endometrioid carcinoma, no
association between copy number changes
and survival was found.
1.5. Serous fallopian tube carcinoma (II)
DNA copy number changes were detected
in all 20 serous fallopian tube carcinomas,
with a mean of 7.0 changes per tumor (Fig-
ure 3). Gains were identified more often
than losses (1.6:1). The most frequent copy
number gains were observed at 8q (75%),
3q (70%), 1q (40%), 12p (40%), 7q (35%),
5p (30%), 20q (30%), 6p (25%), 11q
(25%), and 20p (25%). The minimal com-
Figure 3. Summary of gains and losses detected by CGH in 20 serous fallopian tube carcinomas. Gains
are shown on the right and losses on the left side of each chromosome. Each line represents an aberration
detected in one tumor sample. High-level amplifications are displayed in bold.
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mon regions of gain at 3q and 8q were
3q25-qter and 8q22-qter. High-level am-
plification was detected in 30% of the tu-
mors, and the minimal common regions
were 8q22-qter (four tumors), 3q25-q28
(three tumors) and 12p (one tumor). The
most common regions of decreased copy
number were at 18q (35%), 5q (30%), 8p
(30%) and 4q (25%).
1.6. Comparison of serous carcinomas of the
fallopian tube, endometrium and ovary (II)
The genetic aberrations detected in fallo-
pian tube carcinomas were compared with
the changes detected in 24 serous endome-
trial carcinomas (I) and 20 serous ovarian
carcinomas (Tapper et al., 1998). The pat-
tern of chromosomal alterations detected by
CGH was very similar in serous carcinomas
of the fallopian tube, endometrium and
ovary (Table 4). The most frequently gained
regions, including those at 3q, 8q, 1q, 5p,
6p, 7q, 12p and 20q, and the most com-
monly lost regions, including those at 4q,
8p and 18q, were alike in these three carci-
nomas. Some differences were observed: gain
at 19q and loss at 15q were found only in
fallopian tube (in 15% and 20% of cases,
respectively) and endometrial (in 21% and
17% of cases, respectively) carcinoma,
whereas loss at 17p occurred only in fallo-
pian tube and ovarian carcinomas (in 15%
and 25% of cases, respectively). In all three
types, gains were more frequent than losses.
2. Allelic analysis of 8p21-p23 and
18q12.3-q23 in ovarian carcinoma (III,
IV)
The samples were informative on average
at 13 of 18 loci studied at 8p (range 9–17),
and at 18 of 27 loci studied at 18q (range
13–25). One serous tumor (sample 210)
showed microsatellite instability of several
markers at 8p and it was excluded from the
analysis because of a possible mismatch-re-
pair-system deficiency. Instability of one to
three markers was seen in six serous tumors:
samples 852, 223 and 412, one marker each
at 8p, samples 852, 810 and 1106, one
marker each at 18q, and sample 1097, three
markers at 18q. In mucinous carcinomas,
one tumor (sample 783) showed instability
of one locus at 8p.
2.1. Comparison of serous and mucinous
ovarian carcinomas
Allelic loss at 8p and 18q regions was more
frequent in serous than in mucinous ova-
rian carcinoma. In serous carcinoma, al-
lelic loss was detected at 8p in 67% (41/
61) and loss at 18q in 59% (38/64) of tu-
mors, whereas in mucinous carcinoma






































































Table 4. Chromosomal changes detected by CGH
in serous fallopian tube (n=20), endometrial (n=24)
and ovarian (n=20) carcinomas.
a
 chromosome arms showing gain in at least 30% and loss




(1/9) of tumors, respectively (p=0.0025
and p=0.018). In addition, at 8p the dele-
tions were larger in serous than in muci-
nous tumors: the average number of mark-
ers with LOH in tumors showing allelic
loss was 9.6 in serous carcinomas and 1.3
in mucinous carcinomas. The only muci-
nous tumor presenting with allelic loss at
18q showed LOH at 12 of 15 informative
markers, and in serous carcinoma, LOH
at 18q was found on average at 12.8 mark-
ers. The mean degrees of LOH of infor-
mative alleles in serous carcinoma were
50% at 8p and 42% at 18q, whereas in
mucinous carcinoma the figures were 1.9%
and 8.3%, respectively (p=0.0008 and
p=0.0013). Grades and stages of mucinous
tumors were lower than those of serous
tumors. However, when taking into ac-
count only grade 1-2 or stage I-II tumors,
the difference in the degree of LOH re-
mained significant.
2.2. Comparison of allelic loss at 8p and 18q
in serous carcinomas
A larger number of serous than mucinous
tumors were analyzed to define the puta-
tive tumor suppressor locus/loci more pre-
cisely at 8p and 18q (62 tumors as regards
8p and 64 tumors as regards 18q). LOH
was seen in approximately 60% of serous
carcinomas at both of these regions (67%
showed loss at 8p and 59% at 18q)
(p=0.46). Allelic loss at all informative
markers was seen in 51% (21/41) of tu-
mors showing LOH at 8p and in 39% (15/
38) of tumors showing LOH at 18q
(p=0.37). Several tumors presented with a
complex pattern of allelic loss at both re-
gions, showing multiple interstitial losses
and retained alleles.
In 51 cases, allelic analysis was per-
formed at both 8p and 18q. In 65% of the
cases (33/51) LOH status was similar (ei-
ther LOH at both 8p and 18q, or no LOH
at either 8p or 18q), and in 35% of the
cases (18/51) LOH status was different at
8p and 18q. The association between LOH
at these regions was not significant
(p=0.13).
2.3. Clinicopathological characteristics
In serous carcinoma, LOH was associated
with tumor grade at both 8p and 18q. At
8p LOH was detected in 36% of grade 1
tumors, in 68% of grade 2 tumors and in
77% of grade 3 tumors (p=0.029), and at
18q in 7.1%, 72% and 77% of tumors,
respectively (grade 1 vs. grades 2 and 3,
p<0.001). No association was found be-
tween LOH and stage of serous tumors. In
mucinous carcinoma, there was no corre-
lation between LOH and clinicopathologi-
cal parameters.
Patients with serous carcinomas show-
ing LOH at 18q had poor overall survival
when compared with patients with serous
carcinomas showing no LOH (p=0.044).
Tumor grade was also associated with sur-
vival (p=0.0009), but the association be-
tween tumor stage and survival did not
reach statistical significance (p=0.058). In
multivariate analysis, only grade was an
independent prognostic factor.
2.4. Minimal common regions of loss in serous
carcinoma
2.4.1. 8p21-p23 (III)
Twenty serous carcinomas showing partial
losses at 8p21-p23 were used to construct
a deletion map. There were three markers
that showed LOH in ≥60% of informative
alleles: D8S499 (8p21.1), D8S552 (8p22)
and D8S1721 (8p23.1). Based on the dele-
tion map, three distinct minimal common
regions of loss could be defined around these
markers: R1 between D8S1810 and
D8S1771 at 8p21.1 (size approximately 7
cM), R2 between D8S1731 and D8S640
at 8p22-8p23.1 (approximately 4 cM) and
R3 between D8S520 and D8S277 at
8p23.1 (approximately 11 cM).
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2.4.2. 18q12.3-q23 (IV)
Twenty-three serous tumors presenting with
partial losses at 18q12.3-q23 were used for
deletion mapping. The highest frequencies
of LOH were seen in the distal part of the
chromosome arm, 18q22-q23. Three mark-
ers showed LOH in >75% of informative
cases: D18S483 (18q22), D18S979 (18q22)
and D18S871 (18q23). Two minimal com-
mon regions of loss could be defined around
these markers: MCRL1 between markers
D18S465 and D18S61 at 18q22 (size ap-
proximately 4 cM), and MCRL2 between
markers D18S462 and D18S70 at 18q23
(approximately 5 cM).
3. Expression analysis of candidate
genes located at 8p21-p23 and
18q12.3-q23
3.1. GATA-4 (III)
The GATA4 gene is located at one of the
minimal common regions of loss detected
in this study (R3 at 8p23.1). In Northern
blotting, GATA-4 mRNA expression was
detected in 62% (16/26) of mucinous and
12% (4/33) of serous ovarian carcinomas.
Immunohistochemistry of normal ova-
rian samples showed GATA-4 in the nu-
clei of surface epithelial cells, particularly
in the metaplastic cuboidal and columnar
cells on the surface and in the inclusion
cysts. Positive immunostaining was noted
in the nuclei of stromal cells in some of
the samples (normal ovary, serous and mu-
cinous carcinomas). Positive nuclear stain-
ing in carcinoma cells was detected in 66%
(49/75) of mucinous carcinomas, but only
in 2.3% (12/528) of serous carcinomas
(p<0.0001). The difference remained sig-
nificant when only grade 1-2 (p<0.0001)
or stage I-II (p<0.0001) tumors were taken
into account.
In mucinous carcinomas, GATA-4 stain-
ing correlated negatively with the grade
and stage of the tumors (p=0.016 for grade,
p<0.0001 for stage). In serous carcinomas,
there was no such association.
Forty-one serous and 10 mucinous tu-
mors were analyzed for both LOH at 8p
and GATA-4 immunostaining. All the se-
rous cases showing allelic loss of the whole
of distal 8p had lost GATA-4 protein ex-
pression and only 1 of 7 cases showing par-
tial deletions including the GATA-4 re-
gion presented with positive GATA-4
staining. Of the 19 serous cases showing
no LOH at distal 8p, only two were posi-
tive for GATA-4 staining. In mucinous
carcinomas two cases showed allelic loss at
one marker located at R3 (249 at D8S1140,
783 at D8S1721) and both of these cases
were positive for GATA-4 immuno-
staining. Seven of the 8 mucinous carcino-
mas showing no LOH at distal 8p had posi-
tive GATA-4 staining and in the one re-
maining sample the staining was not in-
terpretable.
3.2. SMAD4, SMAD2 and DCC (IV)
SMAD4, SMAD2 and DCC genes are lo-
cated at 18q21.1. In normal ovarian tissue
positive immunoreactivity of SMAD4
(moderate to strong), SMAD2 (weak) and
DCC (focally weak to moderate) was ob-
served in surface epithelial cells and a pro-
portion of stromal cells. Lost or very weak
expression of SMAD4, SMAD2 and DCC
was found in 28% (17/60), 28% (17/60)
and 30% (18/60) of serous carcinomas, re-
spectively. There was a tendency towards a
higher amount of lost expression of
SMAD4, SMAD2 and DCC in tumors with
LOH at 18q21.1 compared with the tu-
mors with no LOH at 18q21.1 (42–46%
and 17–20%, respectively). When analyz-
ing the additive effect of all three factors, a
total of 83% of the tumors with LOH at
18q21.1 had lost SMAD4, SMAD2 and/or
DCC expression, whereas 40% of the tu-
mors with no LOH at 18q21.1 had lost ex-




4. P53 immunostaining and clinical
correlates in serous ovarian carcino-
mas (V)
4.1. P53 immunohistochemistry
Weak P53 immunopositivity was detected
in a small proportion of normal ovarian sur-
face and fallopian tube epithelial cells. P53
staining was interpretable in 505 of 522
serous ovarian carcinomas. Forty-one per-
cent of the tumors showed weak immuno-
staining similar to that seen in normal epi-
thelium and were regarded as showing “nor-
mal P53 staining”. Two patterns of aber-
rant P53 expression were identified: in “ex-
cessive staining”, the majority of tumor cells
(>50%) showed homogeneous moderate or
strong immunopositivity, and in “negative
staining” all tumor cells were completely
devoid of staining. Excessive P53 staining
was seen in 43% and negative staining in
16% of the tumor samples.
4.2. Association with clinicopathological
characteristics
Both excessive and negative P53 staining
were associated with advanced stage
(p<0.0001 for both), high grade (p<0.0001
for both), large residual tumor size
(p<0.0001 for both), presence of ascites
(p<0.0001, p=0.0088) and greater patient
age (p<0.0001, p=0.0009) compared with
tumors showing normal P53 staining.
4.3. Association with overall survival
Both excessive and negative P53 staining
were associated with poor overall survival
compared with tumors showing normal P53
staining (p<0.0001 for both comparisons).
There was no significant difference in over-
all survival between tumors showing exces-
sive and negative P53 staining (p=0.21),
and they were combined as one group, called
“aberrant P53” for further analyses.
Univariate analyses of clinicopathological
characteristics and P53 status in the whole
cohort and distinct subgroups are shown in
Table 5. Multivariate analysis showed in-
dependent prognostic value for residual tu-
mor size, FIGO stage, patient age, tumor
grade and P53 status (Table 6). When stage
I and stage III carcinomas were analyzed
separately, P53 status was still an indepen-
dent prognostic factor of overall survival
(Table 6).
4.4. Association with response to therapy and
disease-free survival
Carcinomas with aberrant P53 staining
more frequently showed no response to
therapy compared with tumors with nor-
mal P53 expression (p<0.0001). This asso-
ciation was also found when stage III
(p=0.0016) carcinomas were analyzed sepa-
rately.
The disease-free survival time of patients
with tumors showing aberrant P53 expres-
sion was shorter than that of those with
normal P53 expression (p<0.0001). This as-
sociation was also seen in stage I (p<0.0001)
and stage III (p<0.0001) carcinomas ana-
lyzed separately.
4.5. Patients treated with platinum-based
combination chemotherapy
In patients treated with platinum-based




































Table 5. Prognostic significance of different factors
for overall survival according to univariate analyses
by log-rank test in serous ovarian carcinoma.
* = not analyzable
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sociations were found as for the whole co-
hort: aberrant P53 expression was associ-
ated with poor overall survival, both in
univariate (p<0.0001) and multivariate
(p=0.042) analyses, poor response to
therapy (p<0.0001) and shorter disease-free
survival (p<0.0001).
Patients who received platinum com-
pounds with cyclophosphamide or cyclo-
phosphamide and epirubicin (group 1: nor-
mal P53, n=95; aberrant P53, n=143) and
patients receiving platinum in combina-
tion with paclitaxel (group 2: normal P53,
n=31; aberrant P53, n=66) were compared
(median follow-up times 115 and 23
months, respectively). In group 1, the 2-
year and 5-year overall survival rates were
94% and 84% for those with normal P53,
and 50% and 28% for those with aberrant



























































Table 6. Cox proportional hazards models of independent prognostic factors for overall survival in serous
ovarian carcinoma.
HR = hazard ratio; CI = confidence interval; ref = reference category; * = not analyzable; ns = non-significant
P53 (p<0.0001). In group 2, the 2-year
and 5-year overall survival rates were 83%
and 75% for those with normal P53, and
71% and 33% for those with aberrant P53
(p=0.075). In group 1, 33% of carcino-
mas with aberrant P53, compared with
61% of carcinomas with normal P53,
showed a complete response to therapy
(p<0.0001). In group 2, a complete re-
sponse was seen in 44% of tumors with
aberrant P53 and 63% of tumors with
normal P53 (p=0.052). In cases of tumors
with aberrant P53, patients treated with
paclitaxel/platinum (n=66) tended to show
better overall survival compared with those
on platinum/cyclophosphamide treatment
(n=143) (p=0.056), but no such associa-






1. Evaluation of the methods
Comparative genomic hybridization is a
powerful method of screening for gains and
losses in tumor genomes and pinpointing
locations of potential oncogenes and tumor
suppressor genes (amplifications and losses)
(Kallioniemi et al., 1992). It has produced
large amount of new knowledge of recur-
rent chromosomal changes in cancers
(Knuutila et al., 1998; Knuutila et al.,
1999), especially in solid tumors, and led
to the identification of genes that play im-
portant roles in cancer development and
progression (Visakorpi et al., 1995a; Anzick
et al., 1997; Hemminki et al., 1998). In
addition to pinpointing locations of impor-
tant genes, the pattern of changes detected
by CGH can also be used as a “fingerprint”
when comparing different tumor types.
Both of these qualities were utilized in this
study.
For more detailed mapping of lost or am-
plified chromosomal regions detected by
CGH, several methods can be used, includ-
ing LOH and FISH analyses as well as new
array-based CGH techniques (Pinkel et al.,
1998; Pollack et al., 1999). In this study,
allelic analysis was used for fine mapping
of recurrent regions of loss. Both in CGH
and LOH analyses a sufficient proportion
of tumor cells in the samples is important
to avoid underestimation of changes. For
this reason, only samples containing over
50% of tumor cells were used for CGH in
this study, and for LOH, microdissection
was used when the proportion of tumor cells
was considered to be too low.
High overall concordance of LOH and
CGH results has been reported, ranging
from 76% to 92% (Iwabuchi et al., 1995;
Joos et al., 1995; Visakorpi et al., 1995b).
In ovarian carcinoma, the concordance has
varied from 56% to 100%, depending on
the locus, and being 84% overall (Iwabuchi
et al., 1995). Various reasons may cause dis-
crepant results between the methods at cer-
tain loci: The resolution of CGH allows
detection of physical deletions of over 10–
20 Mb in length. If loss is small and dis-
continuous, or if LOH is due to mitotic re-
combination, it cannot be detected by CGH
(Kallioniemi et al., 1994). Areas of homozy-
gous loss may or may not be seen by CGH,
depending on the size of the deletion. In
LOH analysis, because of PCR-based
method, homozygous loss may be seen as
retention of heterozygosity due to amplifi-
cation of a small amount of contaminating
DNA from non-neoplastic cells. Thus, in
this study, the loci showing heterozygosity
in the deletion maps were checked for sizes
of allele peaks, and no reduction of inten-
sity suggesting homozygous loss was de-
tected. When one allele is lost and the other
allele is duplicated (uniparental disomy),
CGH shows no copy number change, but
LOH is observed. Gain or amplification of
one allele may also appear as LOH, because
scoring for LOH is based on quantitative
analysis of the intensity of the two alleles
(Orsetti et al., 1999; Rodriguez et al.,
2000). If LOH is suspected to represent gain
of one allele rather than loss of the other
allele, the term allelic imbalance has been
used instead of allelic loss. Because our
analyses were based on previous results
showing frequent loss detected by CGH in
ovarian carcinomas at the studied regions,
LOH was unlikely to be due to gain of chro-
mosomal material in this study. Compari-
son of these results, however, was not pos-
sible, because most cases analyzed for LOH
in this study had not been analyzed by
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CGH. In conclusion, advantages of CGH
and allelic analysis complement each other;
whereas allelic analysis has higher resolu-
tion, CGH is able to detect the direction of
the change (loss or gain).
2. Chromosomal changes in endo-
metrial carcinoma – comparison of
serous and endometrioid histological
types (I)
Most of the endometrial carcinomas previ-
ously analyzed cytogenetically or by CGH
have been of the endometrioid histological
type, since it accounts for the majority of
endometrial carcinomas. The finding of
relatively simple chromosomal changes in
the endometrioid type, in the present study,
is in agreement with previous cytogenetic
analyses. As in this study, the most frequent
aberration found in cytogenetic and CGH
studies (Table 1) has been the gain at 1q
(Fujita et al., 1985; Couturier et al., 1986;
Couturier et al., 1988; Milatovich et al.,
1990; Shah et al., 1994; Bardi et al., 1995;
Sonoda et al., 1997a; Suzuki et al., 1997;
Suehiro et al., 2000; Baloglu et al., 2001).
Chromosome arm 8q is the second most
common region showing increased copy
number in CGH in the present and other
studies. In contrast to the present results,
other CGH studies have revealed a higher
number of chromosomal changes, particu-
larly losses, in endometrial carcinoma
(Sonoda et al., 1997a; Suzuki et al., 1997;
Suehiro et al., 2000; Baloglu et al., 2001).
The explanation for this discrepancy is un-
known. It is not likely to be due to less ag-
gressive pathological characteristics of the
tumors, since our material was selected to
match the serous endometrial carcinomas
and thus it was of higher stage and grade
than endometrioid carcinomas in general.
Karyotypic or CGH analyses have been
performed only on a few cases of serous en-
dometrial carcinoma (Bardi et al., 1995;
Sonoda et al., 1997a; Tibiletti et al., 1997).
In accordance with the literature, the
present results showed extensive and com-
plex aberrations in serous endometrial car-
cinomas (Bardi et al., 1995; Tibiletti et al.,
1997). The most common aberration found
in the present study was gain at chromo-
some arm 3q, which was seen in half of the
serous samples. Gain and amplification at
3q has also been seen frequently in ovarian
carcinoma as well as in cancers of the uter-
ine cervix and lung (Knuutila et al., 1998).
Several putative oncogenes have been pro-
posed at the distal part of 3q. PIK3CA,
which encodes a catalytic subunit of
phosphatidylinositol 3-kinase and is located
at 3q26, has been found to be amplified in
ovarian cancers. Amplification was found
to be associated with increased PIK3CA
transcription, protein expression and PI3-
kinase activity (Shayesteh et al., 1999).
Recently, another candidate oncogene, EIF-
5A2, was isolated at 3q26. It was ampli-
fied and overexpressed in primary ovarian
cancers and ovarian cancer cell lines (Guan
et al., 2001). PIK3CA and EIF-5A2 might
be affected in serous endometrial carcinoma,
but copy number and expression of these
genes has not been studied in endometrial
carcinoma. The gains at 3q were usually
large and in addition to the above-men-
tioned genes, the affected region contains
many other genes that might be involved
in serous endometrial carcinoma.
In the present study, serous and endo-
metrioid endometrial carcinomas were
found to be distinct in respect to their DNA
copy number karyotypes. Chromosomal
imbalances were more common and com-
plex in serous than in endometrioid carci-
nomas. Several regions, including 3q, 5p,
6p, 7q, 8q, 11q and 19q, showed copy num-
ber gains more frequently in the serous than
in the endometrioid type. Losses were less
frequent than gains in both histological
types, but in particular they were rare in
the endometrioid type. Serous carcinoma
has poor prognosis (Hendrickson et al.,
1982; Bokhman, 1983), and according to




behavior associated with the extent of ge-
nomic change. Recently, molecular evidence
has emerged supporting distinct pathways
of pathogenesis for these two types of en-
dometrial carcinoma. Mutations of PTEN
are frequent in endometrioid carcinoma and
endometrial hyperplasia, but they are not
seen in serous carcinoma (Kong et al., 1997;
Risinger et al., 1997; Tashiro et al., 1997a;
Levine et al., 1998; Maxwell et al., 1998).
In contrast, mutations of P53 and protein
overexpression are typical of serous carci-
noma and its putative precursor EIC, but
they are infrequently found in endometrioid
carcinoma and not seen in endometrial hy-
perplasia (Kohler et al., 1992; Sherman et
al., 1995; Moll et al., 1996; Zheng et al.,
1996; Tashiro et al., 1997b; Lax et al.,
2000). Microsatellite instability and KRAS
mutations have been identified in subsets
of endometrioid, but not of serous carci-
noma (Risinger et al., 1993; Duggan et al.,
1994a; Caduff et al., 1995; Tashiro et al.,
1997c; Lax et al., 2000). To summarize, the
present and previous findings suggest dis-
tinct pathogenetic pathways for serous and
endometrioid endometrial carcinomas, and
support the clinicopathological model of
two types of endometrial carcinoma
(Bokhman, 1983).
3. Chromosomal changes in serous
fallopian tube carcinoma – compari-
son with serous endometrial and
ovarian carcinomas (II)
Interestingly, the pattern of chromosomal
changes found in serous endometrial car-
cinoma (I) resembled the pattern found in
serous ovarian carcinoma (Tapper et al.,
1998), which prompted us to analyze an-
other serous carcinoma of Müllerian ori-
gin, fallopian tube carcinoma. Serous fal-
lopian tube carcinoma presented with fre-
quent and complex chromosomal aberra-
tions, which is in agreement with previ-
ous data (Bardi et al., 1994; Heselmeyer
et al., 1998). The regions of the most com-
mon copy number changes in the present
study showed similarity with those de-
tected by Heselmeyer et al. (Heselmeyer
et al., 1998). In particular, the most fre-
quently gained regions were very similar,
with common copy number increases at 3q,
8q, 1q, 5p, 7q and 12p in both studies.
Both studies also revealed frequent copy
number decreases at 18q and 8p. However,
in the study by Heselmayer et al. there were
common losses at 16q, 22q and 1p, which
were not detected in the present study. One
reason for this discrepancy may be sensi-
tivity of these regions to artefacts (Kallio-
niemi et al., 1994; Bjorkqvist et al., 1998).
The pattern of chromosomal changes de-
tected in fallopian tube carcinoma by CGH
was very similar to those found in serous
endometrial (I) and serous ovarian (Tapper
et al., 1998) carcinomas. All these carcino-
mas showed complex and extensive aberra-
tions, with gains predominating over losses,
and the most frequent copy number gains
and losses showed similarity. Furthermore,
the pattern of changes in serous carcino-
mas was different from those detected in
other histological types of endometrial and
ovarian carcinoma (endometrioid and mu-
cinous) (I) (Tapper et al., 1997). The epi-
thelia of the uterus, fallopian tube and ovary
share a common embryological back-
ground, and serous carcinomas derived from
these organs present with a similar appear-
ance in histopathological examination. Mu-
tations of P53 and overexpression of the
protein are frequently observed in all these
carcinomas (Milner et al., 1993; Klemi et
al., 1995; Lacy et al., 1995; Sherman et al.,
1995; Tashiro et al., 1997b; Zheng et al.,
1997). Clinically, they all exhibit invasive
behavior, early dissemination and poor
prognosis (Kurman, 1994). These findings
suggest that serous carcinomas of the en-
dometrium, fallopian tube and ovary share
common genetic events in tumor develop-
ment and progression.
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4. Allelic analysis of ovarian carcinoma
at chromosome arms 8p and 18q –
comparison of serous and mucinous
histological types (III, IV)
Chromosomal regions that showed frequent
losses in CGH analyses, distal parts of chro-
mosome arms 8p and 18q, were mapped
further using allelic analysis. The microsat-
ellite markers chosen for allelic analyses at
these regions showed a high level of infor-
mativeness: on average 70% of the loci were
informative in each sample. Replication er-
ror of several microsatellites, indicating MSI
phenotype (Boland et al., 1998), was seen
only in one serous tumor. The frequency of
MSI was lower than reported for ovarian car-
cinoma in general (Fujita et al., 1995; King
et al., 1995; Sood et al., 2001). However,
consistent with the present findings, a lower
prevalence of MSI has been found in the
serous histological type (Fujita et al., 1995;
King et al., 1995; Haas et al., 1999).
In the present study, at both 8p and 18q
allelic losses were more frequent and exten-
sive in serous than in mucinous ovarian car-
cinomas. Previously, a higher frequency of
LOH at other chromosomal arms, includ-
ing 6q, 13q, 11p, 11q, 17p, 17q, 19q and
22q, has been reported for serous versus non-
serous carcinomas, especially mucinous ones
(Sato et al., 1991; Pieretti et al., 1995; Papp
et al., 1996; Lu et al., 1997; Bryan et al.,
2000; Launonen et al., 2000). These regions
may contain tumor suppressor genes rel-
evant to serous ovarian carcinoma, but the
high frequency of changes may also reflect
general genomic instability of serous carci-
nomas. Many of the previous LOH studies
on ovarian carcinoma have not revealed dif-
ferences between the histological types, in-
cluding those that have concentrated on
chromosome arms 8p and 18q (Chenevix-
Trench et al., 1992; Dodson et al., 1993;
Yang-Feng et al., 1993; Osborne and Leech,
1994; Wright et al., 1998; Brown et al.,
1999; Takakura et al., 1999; Pribill et al.,
2001). This may be partly due to the small
number of non-serous tumors, especially
mucinous tumors, included in these stud-
ies. On a molecular level, differences be-
tween serous and mucinous ovarian carci-
nomas have been identified in alterations
of KRAS and P53. KRAS mutations are
typical of mucinous carcinomas, but rare in
other histological types, whereas P53 mu-
tations are frequent in serous carcinomas and
uncommon in mucinous ovarian carcinomas
(Enomoto et al., 1991b; Milner et al., 1993;
Ichikawa et al., 1994; Klemi et al., 1995;
Suzuki et al., 2000a). In addition, distinct
chromosomal aberrations have been identi-
fied in serous and mucinous ovarian carci-
nomas in cytogenetic analysis and CGH
(Pejovic et al., 1992b; Diebold et al., 1996;
Diebold et al., 1997; Tapper et al., 1997).
Consistent with these findings, the present
results suggest a different molecular patho-
genesis for serous and mucinous ovarian
carcinomas.
5. Fine allelotype mapping and expres-
sion of candidate genes (III, IV)
5.1. LOH at 8p21-p23 and 18q12.3-q23 in
serous ovarian carcinoma
Because LOH was more frequent and ex-
tensive in serous carcinomas than in muci-
nous carcinomas, a larger number of serous
carcinomas were analyzed at both 8p and
18q to define the putative tumor suppres-
sor locus/loci more precisely. Similar over-
all patterns of allelic loss were found at
8p21-p23 and 18q12.3-q23 in serous ova-
rian carcinomas. At both regions LOH was
seen in approximately 60% of tumors and
about half of these tumors showed LOH at
all informative markers. Complex patterns
of LOH showing multiple interstitial losses
and retained alleles between them were de-
tected in several tumors at both regions.
This phenomenon has also been identified
at other chromosomal regions in ovarian car-
cinoma (Lu et al., 1997; Fullwood et al.,




nificantly associated with each other. This
suggests that the events are not linked and
the frequent LOH seen at these sites is not
a random consequence of genomic instabil-
ity.
In the present study, three minimal com-
mon regions of loss were defined at 8p21-
p23 (Figure 4). Other allelotype studies of
ovarian carcinoma have each revealed one
to three smallest regions of loss at 8p
(Wright et al., 1998; Brown et al., 1999;
Pribill et al., 2001). However, these stud-
ies involved analysis of various histologi-
cal types of ovarian carcinoma as a single
disease entity and used different selections
of microsatellite markers, therefore mak-
ing direct comparison of the results diffi-
cult. Only the analysis by Wright et al.
included several markers distal to D8S261
(8p22). The distal and middle regions
found by them overlap with the R3 and
R2 regions defined in the present study.
The most distal region found by Pribill et
al. was around marker D8S261. The
telomeric breakpoint of this region was
difficult to define, because the more distal
marker D8S1992 showed a higher fre-
quency of LOH than D8S261. This region
overlaps with the R2 region of the present
study. The studies by Pribill et al. and
Brown et al. revealed the highest frequen-
cies of allelic loss at marker D8S136, which
was not included in the present study.
However, the centromeric breakpoint of
this region defined by Pribill et al. extends
more proximally and this region overlaps
with the R1 region of the present study.
The most proximal region defined by
Pribill et al. was located around markers
that were not included in the present study.
Despite the differences in tumor material
and markers used in these studies, the find-
ings suggest the presence of more than one
tumor suppressor gene at 8p involved in
ovarian carcinoma, especially its serous his-
tological type.
The highest frequency of allelic loss at
18q was found distal to 18q21 in the
present study. Two minimal common re-
gions of loss were identified: one between
D18S465 and D18S61 at 18q22 and the
other between D18S462 and D18S70 at
18q23. To our knowledge, the present work
represents the first detailed allelotype map-






















































n=61 n=9 n=40 n=70
Figure 4. Integration map of minimal common
regions of LOH at 8p12-p23 in ovarian carcinoma:
A the present study (III), B study by Wright et
al., C by Brown et al. and D by Pribill et al.
(Wright et al., 1998; Brown et al., 1999; Pribill
et al., 2001). The approximate loci of anchor mark-
ers from Genemap’99 are shown on the right side
of chromosome 8p figure.     , markers used in each
study. Shaded areas, minimal common regions of
loss (extend to the flanking markers retaining het-
erozygosity). R1, R2 and R3, minimal common
regions of loss in the present study. Numbers of
tumor samples analyzed in each study are shown
under the corresponding column.
39
one study, including six markers at 18q21,
the highest frequency of allelic loss was
found at marker D18S474 (Takakura et al.,
1999). The marker showed LOH in 36%
of the cases, a frequency which is in agree-
ment with the present findings concern-
ing that marker. However, the study by
Takakura and colleagues was limited to
markers located at 18q21. Consistent with
the present results, in another study, includ-
ing five markers at 18q, the highest fre-
quency of losses was found distal to 18q21
(Chenevix-Trench et al., 1992). In that
study only two markers were located at
18q22-q23 and a more detailed analysis of
the distal region was not possible. The find-
ings in the present study suggest the pres-
ence of as yet unknown tumor suppressor
genes at 18q22-q23 in serous ovarian car-
cinoma.
5.2. GATA-4
GATA4 is located at 8p23.1 in the R3
minimal common region of loss in the
present study. GATA-4 belongs to a family
of zinc finger transcription factors, which
by binding to a consensus GATA motif
present in the promoter of target genes
regulate cell differentiation and prolifera-
tion in a variety of tissues including the
ovary. GATA-4 is expressed in the normal
surface epithelium of human and mouse
ovary (Heikinheimo et al., 1997; Laitinen
et al., 2000). GATA binding sites have been
identified in the promoters of Müllerian in-
hibiting substance (MIS) and inhibin-α
genes, and GATA-4 has been found to regu-
late the expression of these genes (Viger et
al., 1998; Ketola et al., 1999; Tremblay and
Viger, 1999; Watanabe et al., 2000). Both
MIS and inhibin-α belong to TGF-ß su-
perfamily, which is known to have tumor
suppressing activities. In the present study,
expression of GATA-4 was lost in most se-
rous ovarian carcinomas, but retained in the
majority of mucinous carcinomas. Loss of
GATA-4 expression has also been reported
in gastric carcinoma cell lines (Bai et al.,
2000). In contrast, an amplicon of 8p22-
p23 containing GATA4 and cathepsin B
has been identified in a subset of esoph-
ageal and gastric cardia adenocarcinomas
(13%) (Lin et al., 2000), and adrenocorti-
cal carcinomas have been shown to express
GATA-4 (Kiiveri et al., 1999). Overall,
little is so far known about the possible role
of GATA-4 in cancer development and pro-
gression.
5.3. SMAD4, SMAD2 and DCC
The putative tumor suppressor genes
SMAD4, SMAD2 and DCC are located at
18q21.1 (Fearon et al., 1990; Eppert et al.,
1996; Hahn et al., 1996). SMAD4 and
SMAD2 are part of the transforming
growth factor-ß signaling pathway. DCC
was found as a gene frequently deleted in
colon carcinoma (Fearon et al., 1990), and
it has been shown to code a receptor for the
axonal chemoattractant netrin-1 (Fazeli et
al., 1997). Mutations of SMAD4 have been
detected in under 5% of primary ovarian
carcinomas studied (Schutte et al., 1996;
Takakura et al., 1999; Wang et al., 2000).
We found lost or reduced expression of
SMAD4 in 28% of serous ovarian carcino-
mas, in accordance with reduced SMAD4
mRNA expression found in ovarian cancer
cell lines (Hu et al., 2000). Previously, de-
letion in one intron of SMAD2 has been
identified in a subset of ovarian carcino-
mas, but no abnormal expression of
SMAD2 was found by Western blotting in
those samples (Wang et al., 2000). This is
in contrast to our finding that 28% of se-
rous ovarian carcinomas showed lost or re-
duced expression of SMAD2. One expla-
nation for the discrepancy could be possible
normal cell contamination in samples used
for Western blotting. In agreement with
the present results, decreased expression of
DCC has been previously reported in a sub-
set of ovarian carcinomas (Enomoto et al.,




5.4. Association of LOH with expression of
candidate genes
Loss of expression of GATA-4, SMAD4,
SMAD2 and DCC was associated with LOH
at the locations of these genes. However,
almost 90% of serous carcinomas without
LOH at 8p23.1 presented with negative
GATA-4 immunostaining, and about 20%
of serous carcinomas that had no LOH at
18q21.1 showed loss of expression of
SMAD4, SMAD2 or DCC. These tumors
may contain small deletions that reside be-
tween the markers and could not be detected
by the LOH analysis. Other mechanisms
including biallelic mutations, regulation at
the transcriptional level or epigenetic events
such as hypermethylation may also cause
down-regulation of expression. On the other
hand, more than 50% of serous carcinomas
with LOH at 18q21.1 presented with posi-
tive SMAD4, SMAD2 or DCC immuno-
staining. If one allele of the gene is deleted,
as indicated by LOH analysis, the other al-
lele of the gene must still be expressed in
these cases and the gene may be function-
ally active. These findings suggest the ex-
istence of other tumor suppressor gene(s) as
additional and maybe prime targets of fre-
quent allelic loss at distal 18q.
6. Clinical associations and prognostic
value of chromosomal and molecular
changes in serous carcinomas (I, III–V)
A serous histological type is regarded as a
poor prognostic factor in endometrial car-
cinoma (Hendrickson et al., 1982), but little
is known of the prognostic factors within
serous endometrial carcinoma. In the
present study, patients with serous endome-
trial carcinomas that showed changes de-
tected by CGH had poor overall survival,
indicating heterogeneity in this disease,
which may be related to the level of genomic
imbalance. An association between genomic
aberrations detected by CGH and patient
outcome has also been reported in endo-
metrioid endometrial carcinoma as well as
in ovarian and breast cancers (Isola et al.,
1995; Iwabuchi et al., 1995; Suehiro et al.,
2000; Suzuki et al., 2000b).
Allelic loss at 8p has been associated with
the tumor grade of ovarian carcinomas
(Dodson et al., 1993; Pribill et al., 2001).
In addition to LOH at 8p, we found an as-
sociation between tumor grade and LOH
at 18q in serous ovarian carcinomas. When
all histological types have been analyzed in
combination, allelic losses at 8p and 18q
have been associated with advanced stage
(Chenevix-Trench et al., 1992; Wright et
al., 1998; Brown et al., 1999; Zborovskaya
et al., 1999; Pribill et al., 2001), but no
such association was seen in our series of
serous ovarian carcinomas. We found an as-
sociation between LOH at distal 18q and
poor overall survival. The present finding
is in agreement with the results of a ge-
nome-wide study of copy number changes
in ovarian carcinoma showing an associa-
tion between loss at 18q and poor survival
(Suzuki et al., 2000b). Also in accordance
with our findings, Suzuki et al. found that
the number of chromosomal changes and
alterations in specific regions were associ-
ated with grade, but not with stage, sug-
gesting that tumor grade is a better mea-
sure of genome evolution than tumor stage
in ovarian carcinoma (Suzuki et al., 2000b).
The biological behavior, response to
treatment and prognosis of apparently simi-
lar cases of ovarian carcinoma are variable.
At the moment, decisions on the use of ad-
juvant therapy are mainly based on the
spread of the disease (stage) and histologi-
cal differentiation (grade). Surgery alone is
regarded as adequate in patients with well
differentiated, stage Ia and Ib ovarian car-
cinomas; others (including all patients with
clear cell carcinomas) receive chemotherapy
(NIH consensus, 1995). In advanced carci-
noma, residual tumor size has proved to be
an important prognostic indicator. Patient
age and performance status are closely re-
lated and both have been shown to have in-
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dependent prognostic significance in ova-
rian carcinoma. The importance of standard
clinicopathological prognostic factors
(FIGO stage, residual tumor size, histologic
grade and patient age), which have previ-
ously been established for all ovarian carci-
noma subtypes together (Makar et al., 1995;
Friedlander, 1998; Chi et al., 2001; Vergote
et al., 2001), was verified for serous ovarian
carcinomas in the present study.
New clinically useful prognostic factors
are needed for ovarian carcinoma. Several
factors are under investigation, but so far,
no molecular marker has shown strong
enough prognostic value for clinical pur-
poses (Friedlander, 1998; Eisenhauer et al.,
1999). The possible prognostic role of P53
alterations in ovarian carcinomas has been
assessed in many studies, with inconsistent
findings (Marks et al., 1991; Hartmann et
al., 1994; Henriksen et al., 1994; Klemi et
al., 1995; Eltabbakh et al., 1997; Rohlke
et al., 1997; Silvestrini et al., 1998; Anttila
et al., 1999; Baekelandt et al., 1999;
Gadducci et al., 2000; Geisler et al., 2000;
Levesque et al., 2000; Fallows et al., 2001).
Several investigators have reported overex-
pression in immunohistochemistry to con-
fer poor outcome, but only four groups to
date have shown an independent prognos-
tic value of P53 immunostaining status
(Klemi et al., 1995; Rohlke et al., 1997;
Baekelandt et al., 1999; Geisler et al.,
2000). In our cohort, P53 expression status
was an independent prognostic factor for
overall survival both at an early stage as well
as in advanced carcinoma, and aberrant P53
predicted a poor response to therapy and a
shorter disease-free survival time. The
present study, indicating a strong prognos-
tic role for P53 status, was distinct from
previous studies in at least three aspects.
Firstly, we analyzed only serous carcinoma,
the type that has previously shown the high-
est frequency of P53 alterations (Milner et
al., 1993; Klemi et al., 1995; Eltabbakh et
al., 1997; Rohlke et al., 1997; Anttila et
al., 1999; Geisler et al., 2000). On the ba-
sis of the results of the present (III, IV) and
previous studies, the molecular background
and biological behavior of various histologi-
cal types of ovarian carcinoma are different
(Enomoto et al., 1991b; Omura et al., 1991;
Sato et al., 1991; Milner et al., 1993; Klemi
et al., 1995; Makar et al., 1995; Diebold et
al., 1997; Tapper et al., 1997; Obata et al.,
1998). Thus, the prognostic value of a given
marker in various subtypes may not be simi-
lar. Secondly, the use of a tissue microarray
technique (Kononen et al., 1998) enabled
evaluation of a large number of samples,
providing power to statistical analyses.
Thirdly, a negative P53 staining result has
previously been interpreted as wild-type
P53. However, only missense mutations
have been associated with increased P53
protein (Casey et al., 1996; Skilling et al.,
1996; Shahin et al., 2000; Reles et al.,
2001), and normal tissues have shown P53
immunopositivity in a small proportion of
cells (V) (Wen et al., 1999). In the present
series, tumor samples with completely nega-
tive P53, distinct from those showing a
normal (wild-type) expression pattern, were
associated with as poor an outcome as those
with excessive P53 staining.
In stage I serous ovarian carcinomas,
where histological differentiation has pre-
viously been identified as the most power-
ful prognostic factor (Vergote et al., 2001),
we found P53 expression status to be a stron-
ger predictor of overall survival than tumor
grade. Based on the present findings, adju-
vant therapy should be considered for stage
I serous carcinomas with aberrant P53, even
if the tumor is well differentiated. In stage
III serous carcinomas, P53 status could aid
in predicting the response to chemotherapy
and identifying patients with particularly
poor prognosis. The value of P53 expression
status in clinical decision-making needs to





Knowledge of the pathogeneses of gyneco-
logical carcinomas is essential in order to
develop strategies for early diagnosis and
optimal treatment of individual patients.
Until now most research on gynecological
carcinomas has been based on the organ of
origin. However, the different histological
types of endometrial and ovarian carcinoma
in this study presented with distinct genetic
changes, and serous carcinomas from dif-
ferent organs showed similar chromosomal
aberrations. These findings emphasize the
importance of histology in classification of
gynecological carcinomas. Appropriate clas-
sification of cancers into biologically mean-
ingful entities is becoming increasingly im-
portant, as more specific and effective treat-
ment modalities are being developed.
Comparative genomic hybridization re-
vealed several regions of the genome that
are likely to contain genes involved in the
development and progression of gynecologi-
cal carcinomas. In the future, recently de-
veloped methods such as CGH and cDNA
microarrays will facilitate investigation of
the affected regions and discovery of the
underlying genes (Schena et al., 1995;
Pinkel et al., 1998; Pollack et al., 1999;
Monni et al., 2001). For comparison of
mRNA expression, e.g. in cDNA microar-
ray analyses, use of appropriate reference
material is essential. However, in the ovary,
normal surface epithelium is scarce and rep-
resents modified mesothelial rather than
epithelial differentiation (Kurman, 1994).
On the basis of the present findings, serous
fallopian tube carcinoma and normal tubal
epithelium might be used as a model to
discover differentially expressed genes that
could be involved in serous ovarian carci-
noma as well.
In the present study, allelic analysis was
used for further mapping of two recurrently
lost regions in serous ovarian carcinoma.
The critical regions were reduced to ap-
proximately 30% at 8p and to 10–15% at
18q, of the size defined in CGH. The de-
finitive locations of the markers and genes
at the minimal common regions of loss will
be revealed on completion of the sequence
of the human genome (Lander et al., 2001;
Venter et al., 2001). Data on the genomic
sequence will allow mutation and epigenetic
analyses of the candidate genes. Based on
the currently available information, the sizes
of the minimal common regions defined in
the present study range from 1.6 Mb to 5.4
Mb. Additional polymorphic microsatellite
markers as well as single-nucleotide poly-
morphisms (SNPs) (Wang et al., 1998;
Lindblad-Toh et al., 2000) can be used for
further mapping of the regions of interest.
Increasing knowledge of the functions of
genes will aid in selecting candidate genes
for structural analyses as well as mRNA and
protein expression analyses.
Tissue microarrays (Kononen et al.,
1998) proved to be efficient for evaluat-
ing the expression of candidate genes and
for linking this information to clinico-
pathological characteristics of tumors and
patient outcome. In the future, tissue ar-
rays constructed from gynecological car-
cinomas can be used for both expression
analyses and DNA copy number detection
of candidate genes. The collection of clini-
cal, pathological and molecular data in the
same database will enable analysis of asso-
ciations between the different factors and
evaluation of possible independent predic-
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